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There has been a significant increase in children’s burns in the past several years 
and figures indicate that children suffer more burns compared to any other age 
groups. The main concern following a burn is the possibility of infections. The aim 
of this project is to construct a unique wound dressing, which enhances healing 
and stimulates wound closure by incorporation of collagen, as well as signalling 
the presence of pathogenic bacteria on colonisation. 
The process of signalling bacterial colonisation was achieved by incorporation of a 
phospholipid based nanocapsule, with a colourimetric response and a mechanism 
for release of a dye. This research invested into finding the optimum phospholipid 
composition to obtain a stable and sensitive system. The signalling device uses the 
biomimetic aspect of vesicles to signal the presence of pathogenic bacteria via the 
effect of secreted toxins on the sensor interface. The modified phospholipid based 
sensors were immobilised into gel matrices and further developed to produce 
prototype dressings. The healing enhancing property was achieved by a thin layer 
of collagen coating. 
This work presents the results obtained from the initial modification process of the 
sensor, to incorporation of the vesicles into gel matrices through to development of 
First and Second Generation Prototype dressings. Verification of stability and 
sensitivity of the vesicles was carried out following each stage of development, 
using clinically isolated strains of pathogenic bacteria. Initial cytotoxicity and 
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1.1. The clinical problem 
 
One of the major problems following a skin injury is infection1, especially if the 
patient in question has a compromised immune system or if the infection is hard to 
detect. Examples illustrating this situation are paediatric scalds. When a child 
suffers from a scald, their body reacts to the burn by presenting with increased 
body temperature, which is much like the symptoms of children with infected 
wound sites. As a result, a swab of the wound site is necessary to prove the 
existence of an infection before administering antibiotics.  This process of 
swabbing requires the removal of any dressing, which can increase chances of 
scarring, infection, or delay the healing process. Furthermore, during the process 
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of testing the child for infection, the condition of the child may deteriorate, with 
potentially fatal consequences. 3 
In order to treat these wounds more effectively and more efficiently, this study 
aims to develop a device which can sense and signal the presence of pathogenic 
bacteria. The ‘intelligent wound dressing’ developed in this study contains a 
bacterial ‘toxin sensor’, which can signal infection without having to swab the 
wound and grow a culture in order to determine the presence or absence of 
infection in the wound.  
1.1.1.  Skin injury 
Skin is the largest organ in the human anatomy, representing 16% of the body 
weight and measuring between 0.2 and 0.3m2 in adults5. Skin is mainly composed 
of the epidermis and the dermis, with the dermis layer being much thicker than the 
epidermis layer7. The skin of newborns and young children is thin; gradual 
thickening of the skin occurs, before a slow thinning of the skin takes place with 
age. The main role of the skin is to serve as a protective barrier against the 
surrounding environment 8. Upon occurrence of a skin injury, this barrier is 
broken, leading to major disabilities and infections that can result in death. All 
wound injuries are at risk of infection, however some patients are more 
susceptible, and some are more severely affected by, wound infections than others. 
Some infections are harder to detect while others are harder to provide treat. In 
order to effectively treat wound injury infections, early detection is crucial. 
Physicians state that an infection of a burn injury is harder to diagnose, especially 
when dealing with paediatric burn injuries3. As a result, development of such a key 
clinical diagnostic tool within a bacterial infection-signalling device for paediatric 
burns was the focus of this study.   
 
1.1.2. Burns  
Burn injuries are a major cause of morbidity and mortality in children10. Each year 
in the USA, over 440 000 children with burn injuries are taken into hospitals12, of 
which approximately 1100 die from related illnesses, causing burn related injuries 
to be one of the most common causes of paediatric death14. The severity of 
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paediatric burns was recognised, and by implementation of effective precautions 
and treatment methods, there had been a decline in the number of deaths due to 
burn-related-injuries15. However, young children under the age of 5 remain part of 
a high risk group, accounting for approximately 18% of all patients with burns16. In 
the past several years in the UK, there has been a significant increase in paediatric 
burn injuries. According to the Children’s Burns Trust (CBT), in 2010 there was an 
average of 10 children under the age of 5 admitted to hospital with burn injuries 
every day.  The majority of these injuries were scalds caused by hot liquids and 
most occurred within the vicinity of their own homes, typically in the kitchen; 
Figure 1.1 illustrates the injury locations concerning children under the age of 5 17.   
 
Figure 1.1: Graph showing burn injury locality of children. Indicating that most 
injuries occur in own homes, most often in the kitchen. 
 
The increase incidents of paediatric burns is not only a problem occurring in the 
USA and in Europe, but also in Asian countries, where the diet involves various hot 
soup-based meals, steamed meals and boiled rice.  Hangang Sacred Heart Hospital, 
a South Korean hospital, which incorporates Asia’s largest burn unit, reported an 
increase in paediatric scald injuries from 72% in 2005 to 87% in 2009, with most 
of these scalds being caused by hot liquid spills. This translates into an increase of 
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The damage caused by scalds does not only involve the pain that the children 
suffer, but also the possibility of scar development, other physical and emotional 
trauma, and even social problems, especially in children under the age of 5.20  
 
1.1.3. Classification of burn injury 
Burn injuries can be categorised into four different classifications depending on 
the depth and the intensity of the burn. Figure 1.2 below shows the histological 
overview of the different degrees relating to the depth of a burn injury. 
 
Figure 1.2: Histological overview of the different classifications of burns in terms 
of the depth of the injury21 
 
The first is the superficial burn, which is also known as a first degree burn. This 
only involves the outer layer of epidermis and healing occurs fairly rapidly, usually 
without scarring. This type of injury can be caused by exposure to the sun and hot 
liquids. The next is a partial thickness burn, also known as second degree burn. 
These burns can be further divided into two groups, the superficial partial 
thickness and the deep partial thickness. As the name suggests, the deep partial 
thickness burn involves a deeper wound site where more than 50% of the dermis 
is damaged. Treatment may involve skin grafting. The superficial partial thickness 
burn is less severe and healing can occur with minimal scarring. Both types of 
partial thickness burns are often caused by hot liquids, flames and chemicals. A full 
thickness burn, also known as a, third degree burn, is more damaging compared to  
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superficial and partial thickness burns, and may involve destruction of nerve fibres 
and underlying structures of the skin22,23,24. 
As well as the classifications described above, burns can be described in terms of 
Total Body Surface Area (TBSA)25. This is a measure used to assess the severity of 
the burn as a percentage. In adults, the ‘rule of nine’ is used to established the 
extent of the burn injury, whereas in children the ‘Lund-Browder’ diagram, as 
shown in figure 1.3 below,  is used to establish the severity of the burn.  
 
Figure 1.3: A. Rule of nines. B. Lund-Browder diagram, taken from the U.S. 
Department of Health & Human Services (http://chemm.nlm.nih.gov/burns.htm) 
 
1.1.4. Treatment of burns  
The standard medical advice for a scald is to cool the affected area with water for 
10-30 mins and cover the area with cling film. Depending on the severity of the 
injury, the patient may be hospitalised to minimise infection. Upon hospitalisation, 
the injured area is cleaned, the dead tissue removed, the area disinfected and a 




1.1.5. Burn infection  
The survival of patients through the critical care stage, without the interference of 
infections, is the major hurdle arising from a burn injury. Infection of burn injuries 
can delay healing, increase pain levels, increase chances of scarring and may even 
lead to death. Due to the moist nature, elevated temperature, and nutrient rich 
environment of a burn wound, burns provide an ideal environment for growth of 
bacteria 27.Infections are known to occur more commonly in young children and 
the elderly patients28. Rapid diagnosis and appropriate treatment is necessary 
when an infection occurs29. However, the major concern when faced with an 
infected burn is that the infection is hard to diagnose. The symptoms related to 
burn injuries, hyperthermia, tachycardia and hyperventilation, are also common to 
patients with infected wound sites. The similarity in symptoms displayed, make 
diagnosis of an infection much more difficult27.  
The most common pathogens isolated from burn wounds are Staphylococcus 
aureus and Pseudomonas aeruginosa, others may include Streptococcus pyogenes 
and Acinetobacter baumannii 3, 30, 31. S. aureus, which is most commonly associated 
with smaller burns, produces several virulence factors such as proteinases and 
collagenases, a variety of exotoxins, such as toxic shock syndrome toxin-1 (TSST-1) 
as well as a range of endotoxins.  
 
1.1.6. Toxic Shock Syndrome  
Toxic shock syndrome is caused by infection and colonisation by a TSST-1 
producing strain of bacteria, most commonly arising from a toxin-producing strain 
of S. aureus. TSST-1 is a superantigen which results in over-stimulation of the 
immune system32. Early detection of an infection caused by a TSST-1 producing 
strain is vital, however the early symptoms are very closely related to the early 
symptoms of infection of non-toxin producing stains, which in turn are very similar 
to the symptoms arising from the pre-existing burn injury32.   
In summary, early diagnosis of infection of burn injuries is vital in reducing the 
mortality rate33.   
7 
 
1.1.7. Clinical diagnosis of infection 
Wound infection includes regular monitoring of the patient’s blood work and vital 
signs, as well as an inspection of the entire wound. The indications clinicians look 
for include conversion of classification of the burn (from partial-thickness to full-
thickness), tissue necrosis and a rapid spread of cellulitis into surrounding healthy 
tissue3.  
Clinicians at the paediatric burn unit at Frenchay Hospital in Bristol follow strict 
guidelines to prevent misdiagnosis.  Misdiagnosis of an infection that is present 
can cause death, and misdiagnosis of a non-existent infection can cause a broad 
cascade of issues including those linked with overuse of antibiotics, adding to the 
global concern of antibiotic resistance. Clinicians at the burn unit in Frenchay 
utilise the flow chart in Figure 1.4 when a child with a burn of any size and depth 
presents with any of the following symptoms: temperature above 39°C; capillary 
refill time of below 3.4 seconds; development of any type of rash, unexplained 





Figure 1.4: Flow chart followed by clinicians at Frenchay Hospital in Bristol in 
diagnosing infections in paediatric patients with burns of any size and depth. Chart 
supplied by Dr. Amber Young (Frenchay Hospital) and Dr. Toby Jenkins (University 
of Bath). 
Most clinical microbiology laboratories globally rely on culturing a sample 
collected by swab of the surface of the skin or a tissue biopsy of the sample, and 
correlating the culture results to the clinical data to identify the infection type as 
well as the strain responsible for the infection. A detailed method of this procedure 







1.1.8. Pathogenic identification method  
Upon successful swabbing of the wound surface, quantitative counts may be 
carried out to obtain the bacterial counts per cm2 of the wound surface. This 
method provides the identification of the pathogen as well as the exact count per 
cm2. However, the process requires swabbing and culturing, which is time 
consuming7.  
Other methods include biochemical analysis, searching for known virulence factors 
or genes coding for specific mechanisms. Recent discoveries of molecular 
diagnostic tools for infectious diseases, such as the use of polymerase chain 
reaction (PCR), have led to a faster identification of the genotypic characteristics of 
the cause of infections. A major advantage of PCR is that the detection of genetic 
material does not require the labour intensive and time consuming process of 




1.1. Wound dressings 
 
Wound dressings can be defined as material(s) used as wound coverings. 
Dressings have been used since 2010 BC, where mixtures of herbs, ointments and 
oils were incorporated into occlusive bandages36. In the mid-20th century, the 
importance of maintaining a moist healing environment was determined, leading 
to the development of moisture-retentive dressings, such as hydrogel-based 
dressings, which are used extensively in the present-day.  
Moisture-retentive dressings are known to not only provide a moist wound 
environment, but also to be beneficial in the healing process of the wound. A 
moisture-rich environment is thought to promote migration of keratinocytes by 
supporting the movement of cells and maintaining the electrical gradient37,38,39.  
Whilst it is important to develop a wound dressing that can detect bacterial 













1.1.1. Commercially available dressings 
Most commercially available burn wound dressings are hydrogel based; some 
incorporate biological matter as well as incorporation of antimicrobial factors. The 
most commonly used burn wound dressings include silver sulphadiazine dressings, 
which incorporate antimicrobial properties due to the silver, and Biobrane TM, 
which has wound healing enhancing properties due to the incorporation of 
collagen derivatives11. 
1.1.1.1. Wound dressings containing silver 
The antimicrobial properties of silver-containing compounds have been exploited 
from as early as 1000 B.C., and due to their antimicrobial properties, silver 
compounds have been developed for use in medicine for centuries40.  
 
Figure 1.5: Silver surfphadiazine 
 
Silver sulphadiazine dressings (Flammazine® and Silvadene®) were one of the 
first, and are still amongst the most commonly used, dressings for the treatment of 
burn wounds41,42.  Despite studies revealing the disadvantages and side effects 
caused by the use of silver sulphadiazine dressings43, it is still used as the 
reference dressing in studies that involve wound dressings comparisons44.  
Furthermore, a recent Cochrane review on dressings incorporating silver has 
concluded that there is insufficient evidence to show the wound healing promotion 
and wound infection prevention effects of dressings containing silver45. Alternative 





1.1.1.2. Biobrane ™ 
   
Figure 1.6: Patients with partial thickness scald injury treated using Biobrane™: A. 
No removal of dressing; B. Dressing removed. (Images supplied by Dr. Amber 
Young, Burns unit, Frenchay Hospital, Bristol, UK.) 
 
BiobraneTM is a biosynthetic membrane skin dressing designed to be used on 
superficial and partial-thickness burn wounds. It is composed of a nylon mesh with 
silicone membrane on which peptides derived from porcine type I collagen are 
bonded to, to create a dressing which can temporarily perform the actions of the 
epidermis layer lost due to the injury. As the wound heals and re-epithelisation 
occurs, the dressing lifts off revealing healed skin beneath the dressing. The 
dressing is designed to provide increased mobility, speed of healing and rate of 
epithelialisation as well as decreasing pain and length of patient hospital stay47.  
BiobraneTM has been shown to be successful in decreasing the length of hospital 
stays. However limitations of BiobraneTM involve steric hindrance of out flow of 
exudate due to the irregularity of pores and crosslinked collagen peptides.  Figure 
1.6 above shows images of two patients treated with BiobraneTM. The patient on 
the left (A) was successfully treated using BiobraneTM. Despite a suspected 
infection, the dressing was left on, and the patient made full recovery with no scar 
formation. The patient on the right (B) was admitted with 22% TBSA partial 
thickness burns and was treated with BiobraneTM. The dressing was removed due 
to a wound site infection. The infection was treated, but the removal of the 
dressing left the patient with permanent scars. These two cases indicate the 






1.1.2. Requirements for an ‘ideal’ wound dressing 
In order to develop an efficient burn wound dressing, the criteria for an ‘ideal’ 
wound dressing have to be met. Several surveys 48,42have been conducted 
involving medical practitioners across the globe in order to create guidelines for an 
‘ideal’ dressing for treatment of burns. These include elements such as the ability 
for a dressing to restore and act as a skin barrier, the ability to absorb excess 
exudate and fluid secreted by the wound, the adherence of tissue, as well as wound 
healing and the antimicrobial properties of a dressing.  
 
1.1.2.1. Restoring skin barrier and wound healing 
The primary and one of the most important roles of any wound dressing is to 
restore the broken barrier, by addition of a protective layer over the breeched area, 
for thermal insulation as well as for infection control49.  
In addition to a dressing which provides a provisional skin barrier, a dressing 
which can aid the process of wound healing, and promote the growth of cells to 
provide a permanent skin barrier, would be beneficial. Epithelialisation is 
promoted when the oxygen level in the tissue is increased, thus a dressing which 
allows gaseous exchange would be valuable to aiding wound healing. Moreover, 
addition of growth factors, such as collagen have been shown to speed up the 
process of epithelialisation9,13. 
1.1.2.2. Tissue adherence  
Recent studies showed that dressings, which are easily removable with minimum 
pain, would be ideal. A study on pain management of burns showed that patients 
with burns suffer a significantly prolonged persistent pain due to frequent 
dressing changes when compared to patients with chronic wounds  50.  
Furthermore, according to a globally distributed survey carried out among burn 
care specialists, the most important burn wound dressing characteristic is a ‘non-




The absorbency of a dressing was found to be an essential property as dressings 
with the ability to absorb large amounts of fluid can be used to manage the exudate 
and wound fluids. Commercially available dressings are able to manage the fluid 
produced by the wound, but there has not been any evidence to show 
improvement in wound healing. As a result the combination of absorbency with 
addition of growth factors may be advantageous51.  
1.1.2.4. Antimicrobial activity  
According to an online survey conducted among clinicians, the antimicrobial 
properties of wound dressings are essential48. This result is further supported by a 
similar survey carried out on the treatment methods chosen for partial thickness 
burns – silver sulphadiazine dressings are the most commonly used dressings for 
treatment of burns42.   
To summarise, according to global surveys involving medical professionals, the 
properties of an “ideal” burn wound dressing for the effective treatment of 
paediatric burns include low tissue adherence, absorbency, and promotion of 







Bacteria are prokaryotic, unicellular microorganisms with free flowing cyclic 
genetic material, unbound by a membrane. Bacterial cells can be found in various 
different shapes such as spheres, rods, spirals and other less common shapes with 
size ranges of a few microns52.  
 
Figure 1.7:  Structure of a prokaryotic cell. Image obtained from Bacterial 
structure, Growth and Metabolism by Richard A. et al.53  
 
Pathogenic bacteria can be broken down into two main groups; opportunistic and 
primary pathogens. Opportunistic pathogens mainly cause disease in individuals 
with compromised or impaired immune systems. An example would be 
Staphylococcus epidermidis; an opportunistic pathogen and one of the most 
important causes of nosocomial infections. By contrast, primary pathogens can 
cause disease in healthy individuals with intact immunological defenses. 
Bacterial infections of a burn injury are the main problems faced during treatment 
which can increase pain, delay the healing process and of particular concern  in 
children, can also cause toxic shock syndrome (TSS), as stated in the previous 
section. The major pathogenic bacteria involved with burns infections are 
Staphylococcus aureus (S. aureus) and Pseudomonas aeruginosa (P. aeruginosa). 
According to a study carried out in Hallym University, Hangang Sacred Heart 
Hospital in South Korea, the most frequently isolated bacteria from a burn patient 
was P. aeruginosa followed by S. aureus. The same study showed that the majority 
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of these isolated bacteria displayed high antibiotic resistance19,18. 
In this investigation, clinically isolated and fully sequenced strains of S. aureus and 
P. aeruginosa were used as highly infectious models. 
 
1.2.2. Quorum sensing  
Quorum sensing can be described as being the communication pathway used by 
both gram-positive and gram-negative bacteria to control cell- density dependent 
gene expression. This process regulates a variety of physiological functions, 
including the regulation of virulence factors and biofilm formation. The quorum 
sensing mechanism involves the production and detection of small extracellular 
molecules known as autoinducers, which trigger mechanisms for the expression of 
certain genes 54.  
 
1.2.3. Biofilms  
Bacteria in nature can exist as single cells in the planktonic phase as well as being 
attached to a surface in communities called biofilms. Biofilms in nature can be 
comprised of a single species as well as multiple species, with a predominance of 
single species biofilms in infected wounds or surfaces of medical instruments, and 
a predominance of multispecies biofilms in the environment. The most widely 
studied biofilm forming bacteria include P. aeruginosa as the gram-negative 
example and S. aureus as the gram-positive bacteria.  Extensive studies of biofilm 
formations suggest that biofilms are a stable phase in their biological cycle which 
involves multiple steps from formation to dissolution of the biofilm. The formation 
of biofilms often involves communication; in P. aeruginosa it is thought to involve 
cell-to-cell communication55. 
The formation of a biofilm follows several stages, as displayed in Figure 1.8.  Firstly 
bacteria attach to a surface; the cells then proliferate and form colonies, followed 
by the final stages of biofilm maturation and detachment of cells. The initial 
attachments of the cells occur by an adsorption process followed by an irreversible 
attachments of cells occurring though the production of adhesins56. The final 
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stages in biofilm growth are the maturation and detachment of cells.  
 
Figure 1.8: Stages of Biofilm formation 57 
 
Biofilms haven been known for their predominance in medical device-related 
infections58, however recent studies have shown the importance of biofilm in 
pathogenesis of burn wound infections 59.  
 
1.2.4. Commonly isolated bacterial strains  
As discussed in a previous section of Chapter 1, the most commonly isolated 
bacteria from infected burn wounds include Streptococcus pyogenes, Acinetobacter 
baumannii, Staphylococcus aureus and Pseudomonas aeruginosa, with 




1.2.4.1. Staphylococcus aureus 
 
 
Figure 1.9: Scanning electron micrograph of Staphylococcus aureus 
x9560magnification (image source: Source: Carr J. H., in MRSA_PHIL #10046, 
Public Health Image Library.) 
 
Staphylococcus aureus (S. aureus) is a gram positive bacterium (Figure 1.9). It is a 
human pathogen and is frequently found in human hair and skin, and yet it is one 
of the most common causes of skin infections60 . Approximately 80% of the 
population are carriers of S. aureus with 20% being persistent carriers and 60% 
irregular carriers61. 30-50% of healthy adults are nasal carriers, 20% are facial 
carriers and 5-10% of adults are skin carriers of this type of bacteria. It can easily 
be spread by means of contaminated wounds and droplets to the surrounding 
environment62. Most importantly, burn site wound infections are commonly 
caused by this type of bacteria, with higher percentages of isolated strains being 
resistant to antibiotics when compared to those isolated from non-burn patients30. 
S. aureus is also commonly isolated from chronic wounds.  In children, S. aureus 
infections can cause toxic shock syndrome, requiring more complex treatment 
methods. 
In this investigation clinically isolated strains of S. aureus were used. Specifically: a 
strain with complete genome sequence, MSSA 476, a TSST-1 positive stain, 




1.2.4.2. Pseudomonas aeruginosa 
 
 
Figure 1.10: Scanning electron microscopy pictures of P. aeruginosa PAO1 
(bar = 1 μm)63 
 
Pseudomonas aeruginosa,(P. aeruginosa), is a rod-shaped, Gram negative and 
opportunistic bacterium, which can grow in a wide range of temperatures 
(including as high as 42°C), with optimum growth temperature of 37°C. The 
bacterium is typically found in water and soil as well as on plant surfaces in the 
planktonic form or in the form of a biofilm, if attached to a surface (Figure 1.10).  
P. aeruginosa is one of the main causes of nosocomial infections with increasing 
incidence of antibiotic resistance64. A recent study performed in Turkey showed 
that 58 out of 170 patients with P. aeruginosa were patients in intensive care units, 
of which 57% had surgical site infection and 13% had catheter related infections 65. 
A major concern is the increase in antibiotic resistance of this bacterium, including 
most penicillins along with a number of other antibiotics. The antibiotic resistance 
is often caused by rapid biofilm formation in a wound environment. As a result, 
any attempt to prevent bacteria from growing needs to be done prior to biofilm 
formation, thus by implication: as soon as a wound is caused66. Bacteria can also 
gain resistance to antibiotics by genetic mutation and horizontal gene transfer. P. 
aeruginosa is also one of the most commonly isolated pathogens in a burn infection. 
The origin of the infection is usually in the human gastrointestinal tract, but 
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colonisation occurs in sites with a compromised immune system, such as a burn 
wound site62. 
In this study, a clinically isolated strain of P. aeruginosa with complete genome 
sequence64, PAO1, was used as a gram-negative and highly infectious model. 
1.2.4.3. Escherichia coli 
 
 
Figure 1.11: False colour SEM (x6836) of E. coli 0157:H7 (image source: Source: 
Carr J. H., in PHIL #10068, Public Health Image Library.) 
 
Escherichia coli (E. coli) are rod-shaped Gram-negative bacteria ranging from 2 to 5 
μm in size67 (Figure 1.11). Generally, the majorities of E. coli strains are non-
pathogenic and harmLess; they are found naturally in the gut flora to protect 
against opportunistic pathogens. Some remain pathogenic and can cause common 
infections such as urinary tract, and gastrointestinal tract infections62. 
In this study, a non-pathogenic strain, DH5α, was chosen as the negative control 
organism. All of the virulence factors have been removed; it is a strain that is often 




1.2.5. Bacterial virulence factors 
Bacterial toxins are substances which affect the host cells in various ways. Bacteria 
secrete two different types of toxins; endotoxins and exotoxins. Endotoxins are 
often embedded within the outer layer of gram-negative bacteria, and can be 
released upon the decomposition of the cell wall following cell death. 52 Exotoxins 
are those which can be secreted by all types of pathogenic bacteria into the 








Figure 1.12: Blood agar plate showing S .aureus (MSSA 476) and P. aeruginosa 
(PAO1) secrete toxins that break red blood cells and that E. coli (DH5α) does not 
secrete these toxins. Acknowledgment: J.Zhou Ph.D. Thesis 2011 
 
There are three different ways in which toxins can interfere with eukaryotic cells. 
Some toxins damage the cell membrane by creating pores within the membrane or 
by dissolving the cell membrane; an example of this would be the α-toxin secreted 
by strains of S. aureus. Other methods involve inhibiting the process of protein 
synthesis or disrupting ion concentration within the cell. The production of 
haemolytic proteins by S. aureus and P. aeruginosa is shown by means of a blood 









1.2.5.1. Exoproteins produced by Staphylococcus aureus 
S. aureus is known to produce a wide range of toxins and exoproteins which 
interfere with human cells, in order to aid the colonisation process. The toxins and 
proteins secreted include lipases, four different types of haemolysin along with 
other types of proteases. There are also exoproteins which are only secreted by 
certain strains such as toxic shock syndrome toxins and leukocidin, and are also 
known as superantigens 69.      
There are four types of haemolysin; Alpha, Beta, Gamma and Delta. Alpha-
haemolysin, also known as alpha toxin, is produced by a wide range of S. aureus 
strains. The mechanism of action is through the formation of pores and lysis of 
eukaryotic cells by these pores within the cell membrane (Figure 1.13).  
 
Figure 1.13: Diagram showing the mode of action of α-haemolysin. This toxin 
creates pores within the bilayer membrane, disrupting the cell. Modified from an 
image from Exotoxins of S. aureus, 2000.  69 
 
More importantly, delta-toxin is one of the main causes of cell death due to damage 
to the cell membrane. Delta-toxin is a very small protein, consisting of a 26-amino 
acid peptide (Figure 1.14), however it is able to cause total disintegration of 
eukaryotic cells. Its mode of action and degree of damage to the cell depends on 
the concentration of the protein released. At lower concentrations, the toxin is 
adsorbed into the membrane and causes disruption in a circular manner. As the 
concentration increases, the toxins aggregate and disrupt the membrane further. 
Upon further increase of the protein concentration, the toxin acts like a surfactant 




Figure 1.14: Mode of action of delta toxin70 
 
Other than haemolysin, some strains of S. aureus are also known to secrete 
superantigens such as toxic shock syndrome toxins (TSST). As mentioned in 
Section 1.1.5, upon infection by TSST-producing bacteria in a paediatric scald 
injury, this toxin can cause serious damage to the child. TSS is potentially fatal and 
immediate treatment is required. However, the symptoms caused by this toxin are 
hard to distinguish from the symptoms of a scald injury, especially in a child69.   
1.2.5.2. Exoproteins produced by Pseudomonas aeruginosa 
P. aeruginosa produces lipases such as phospholipase C, another class of 
membrane damaging protein. Its mode of action is to cleave phospholipids in a 
membrane bilayer71,72,73. This type of protein hydrolyses the polar head group of a 




Figure 1.15: Diagram showing site of cleavage of phospholipid by phospholipase C. 
This toxin breaks down phospholipid membranes damaging the polar head group. 
This cleavage site remains the same in other phospholipids 72. 
 
Rhamnolipids are a type of bio-surfactant produced by P. aeruginosa. They have 
been known to inhibit microbial growth by lysing cells74 or causing alteration to 
the membrane structure by acting on the lipid or the surface proteins of the cell75. 
Results from studies have demonstrated the antimicrobial properties of these 
rhamnolipids against gram-positive bacteria76. As a result of these mechanisms, 
rhamnolipids are also thought to be one of the lipid membrane damaging agents.  
1.2.5.3. Regulation of virulence factors 
In the case of S. aureus, certain virulence factors, especially those of interest in this 
study, the exoproteins, are regulated by the quorum sensing system. Quorum 
sensing is a system controlled by the population density of bacteria and thus 
stimulates and regulates processes depending on the population density77.  
 
Figure 1.16: Regulation of virulence genes by S. aureus79 
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During the early growth stage of bacteria, the gene encoding for surface adhesion 
for formation of biofilm is stimulated. As the bacterial population density increases 
and the growth stage reaches its exponential phase, the expression of the adhesion 
gene decreases, and the expression of the gene coding for exoproteins production 
is stimulated78. Figure 1.16 illustrates the secretion of virulent proteins such as 
TSST-1 and α-toxin at the stationary phase following the exponential growth phase 
of a bacterial population.  
 
Figure 1.17: Accessory gene regulatory system. Acknowledgement: Dr. Toby 
Jenkins, University of Bath.  
 
The accessory gene regulatory (AGR) system is the process that directly controls 
the up-regulation and down-regulation of toxins and virulence factors.  The 
processes which occur are illustrated in the diagram in Figure 1.17. The expression 
of AGR gene is stimulated by the binding of Sar A protein to sequences which are 
upstream of the AGR gene. The stimulation of the AGR gene causes the production 
of AGR A, B, C. AGR B is a cytoplasmic membrane protein, which is cleaved to form 
AGR D –derived cyclic peptides, also known as thiolactone. As the concentration of 
thiolactone increases outside the cell, phosphorylation of AGR C, a cytoplasmic 
membrane sensor, is stimulated. The phosphorylated form of AGR C subsequently 
phosphorylates AGR A, which activates the production of RNA III. The activation of 
RNAIII causes an up-regulation of toxin production80.   
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As a result, an increased bacterial population increases the concentration of AGR 
D-derived cyclic peptide, which promotes phosphorylation of AGR C and AGR A, 
resulting in activation of RNAIII and thus up-regulation of toxin production.  
Up-regulation of this system results in the production and secretion of the 
membrane-damaging proteins. Down-regulation of this process, however, results 
in minimal or no production, and thus no secretion of these proteins80,81.   
Various different strains of S. aureus were investigated for use as the gram-positive 
model. The investigated strains include MSSA 476 (generic clinical isolate), 
RN3282 (TSST positive) USA300 (LAC) RN6390B (AGR+) RN6911 (genetic 
modification to obtain AGR-).  
1.2.5.4. Regulation of virulence factors in P. aeruginosa  
Along with S. aureus, the virulence factors of P. aeruginosa are also governed by 
the quorum sensing mechanism. P. aeruginosa produces autoinducer - signal 
molecules used for cell- to-cell communication, a key requirement for activation of 
virulence factors and genes such as LasR and lab82.  The autoinducers bind to the 
regulatory proteins on the surface of the cells and induce stimulation of gene 
expression. This promotes the production of exoproteins such as rhamnolipids, 
which have been found to be one of the main proteins responsible for damage of 
lipid bilayer membranes. As well as stimulating the production of exoproteins, the 
binding of autoinducers increases the production of further autoinducers. As a 
result, a high density of cells in a localized area gives rise to a high concentration of 
these autoinducers in the localized area, which in turn causes further stimulation 




1.3. Lipid vesicles 
 
The biocompatibility and biomimicry exhibited by lipid vesicles has enabled their 
development for a wide range of uses such as cellular models and drug delivery 
vehicles. In addition, their ability to encapsulate both hydrophilic and hydrophobic 
drugs lead to the development of vaccines, arthritis treatments and hormone 
replacement therapies83.  
Recent advances have focused on the development of stimuli-sensitive vesicles, 
which lyse upon a specific environmental trigger, allowing controlled and 
monitored delivery of bioactive ingredients to target sites. Targeted drug delivery 
using vesicles has been studied using various different environmental triggers 




Figure 1.18: showing schematic representation of lysis of vesicle upon contact 
with bacterial toxin 
 
Previous research conducted by this group focused on biological-enzyme-triggered 
lysis of vesicles, utilising the principal that vesicles can be designed to mimic 
eukaryotic cells85. Certain pathogenic bacteria produce and secrete membrane 
damaging proteins such as exotoxins, which aids bacterial colonisation by inducing 



















designed to mimic eukaryotic cell membranes, vesicles can also be designed to 
mimic this process and lyse upon contact with bacterial membrane-damaging 
proteins.   
This study aimed to develop a eukaryotic cell mimicking biosensor, which can 
detect and lyse upon contact with membrane damaging proteins secreted by 
pathogenic bacteria. Figure 1.18 depicts a schematic of the project concept.  
 
1.3.1. Lipid compositions of biological membranes 
The majority of biological membranes are composed of proteins and lipids. The 
major lipid components found in bio-membranes include glycerophospholipids 
(also known as phospholipids), spingolipids and sterols86.  
 
1.3.2. Phospholipids 
Glycerophospholipids (PL) are molecules derived from glycerol molecules. Lipids 
with the backbone composed of sn-glycerol 3-phosphate and fatty acid alcyl chains 
form the basis of phospholipids such as phosphatidylcholine (PC), 
phosphatidylethanolamine (PE) and phosphatidylglycerol (PG). The carbon chain 
length of lipids ranges from 14 to 22, with predominance of 16 and 18 found in 
biological membranes.  
Phospholipids are amphiphilic molecules and thus contain a polar hydrophilic 
head group, and a long fatty acid hydrocarbon tail group. In solution, these 
molecules align with all head groups facing the same direction, in order to 
minimize the energy of repulsion. Above a critical concentration, the lipids 
aggregate to form micelles and lipid vesicles. This critical concentration is known 
as the critical micelle concentration (CMC).  
PCs are one of the most abundant lipid types in eukaryotic cells and are the most 
readily available; PCs were used as the main constituent of the vesicles developed 




1.3.3. Sterols  
Sterols include lipids such as cholesterol, which are major and essential 
components of eukaryotic cell membranes.  The cholesterol concentration of a 
eukaryotic membrane is variable within a 0~25% cholesterol concentration range.  
 
 
Figure 1.19: Chemical structure of Cholesterol 
 
Cholesterol depletion studies in eukaryotic cells showed that many of the cellular 
functions involved the presence of cholesterol within the membrane. Cholesterol is 
also thought to play a major role in the bacterial virulence, as it can act as binding 
sites for certain proteins produced by bacteria87.  
 
1.3.4. Principal of vesicle formation 
In 1925 Gorter and Grendel reported that lipid membranes of eukaryotic cells 
were arranged in a bilayer, with the hydrophobic tailgroups facing the core of the 
membrane and the hydrophilic headgroups facing the aqueous layer. This can be 
easily achieved by using the correct lipid compositions above a critical 
concentration88.  
 
1.3.4.1. Lipid polymorphism 
Due to the amphiphilic nature of lipids, spontaneous micelles can be formed, as 
well as bilayers and lipid vesicles in aqueous solutions. The driving force of this 
process is minimization of energy due to unfavourable non- polar and polar 
interactions, as well as the maximisation of polar-polar interactions between the 
hydrophilic, polar head groups and water molecules89.  
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Depending on the nature of the lipids, different structures can be formulated. This 
is due to the differences in the shape parameter of lipids. Figure 1.20 shows the 









Figure 1.20: Lipid angle diagram - A:  Shape parameter (S), S>1.2; B: S=1; C: S<0.6 
 
As previous stated, the shape of the lipid aggregates is determined by the shape 
parameter of the lipid, which is the ratio of the volume of the lipid to the product of 
the area of the polar head group and the length. This is defined by the equation 
below, where S is the shape parameter,   is the volume,    is the area of the polar 
headgroup and    is the maximum length of the acyl chain.  

















PCs have a shape parameter of approximately 1, thus, according to Figure 1.20, 
they are cylindrical in shape, and can form bilayers with lamellar aggregates.  
However, the shape parameter can only be used to predict and define the shapes 
formation of single-phospholipid structures. In order to predict the shape 
formation of a lipid mixture, the average shape parameter (P) can be used:  
    
          
             
  
        
           
 
Where vx and vy are the volume of the two lipids used, ax and ay  are the polar head 
group areas, Re is the molar ratio (Ny/Nx) and h is the average thickness of the 
mixed monolayer. When P-parameter value equals one, the average cross sectional 
area of the acyl chain equals the average cross sectional area of the head groups, 
thus formation of a cylindrical, planar bilayer, formation.  
The planar bilayers follow a so-called self-assembly principal to form closed 
bilayer systems such as vesicles, to minimise the energy cost 90.  
1.3.4.2. Principals of lipid self-assembly 
The formation of vesicles from planar bilayer structures depends on the energy 
barrier trade-off. The planer bilayer system can be ‘opened’, with the end acyl 
chain groups exposed to the surrounding, or ‘closed’ by bending the bilayer system, 
to obtain a system with no exposed acyl chain.  
In an ‘opened’ planar bilayer, the spacing between the molecules will be 
thermodynamically favoured over the ‘closed’ bilayer, where the close packing of 
the molecules will change the molecular spacing, requiring more energy to 
maintain the structure. However in an aqueous media, the interaction of the 
aqueous phase with the ‘opened’ bilayer will be thermodynamically unfavourable, 
compared to the interaction of the aqueous phase with the ‘closed’ bilayer.  Thus, 
depending on the surrounding media, the bilayer will exist as the more 
thermodynamically favourable state. And the formation of vesicles is due to the 











Figure 1.21: Self-assembly of lipids into different shapes as concentration 
increases91 
 
Lipids can self-assemble to form vesicles of various sizes. These can be divided into 
four main categories, small unilamellar vesicles (SUV), large unilamellar vesicles 
(LUV), giant unilamellar vesicles (GUV) and multilamellar vesicles (MLV). SUVs are 
approximately 20-50nm in diameter, consist of a single lipid bilayer and are 
thermodynamically unstable due to their small size.  
LUVs have diameters ranging between 100nm up to 5µm. These can be made by 
free-thawing methods, which induce fusion of SUVs, followed by extrusion through 
polycarbonate filters that produce uniform LUVs. 
GUVs are approximately 5 to 300 µm in diameter. These are large liposomes which 
can be viewed with optical microscopy. The size of these giant liposomes bares a 
closer resemblance to eukaryotic in comparison to other liposomes. As such, they 
can be viewed as excellent candidates for use as cell models, however, due to their 
large diameter, they hold large internal volumes, rendering them fragile92.  
As the name suggests, MLVs are multi-compartmental vesicles and thus consist of 
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1.3.4.3. Lamellar phases  
As mentioned above, phospholipids are cylindrical in shape, and therefore form 
lamellar aggregates. Within the aggregate, and depending on the lipid chain length, 
temperature and pressure, lipid aggregates can be in different lamellar phases93. 
Typically there are two major phases: 
- Lα– lamellar liquid-crystalline phase 
- Lβ– lamellar gel phase 
 
The lamellar gel phase is when the bilayer is at a ‘solid’ state and the lamellar 
liquid-crystalline phase is when the bilayer is at the ‘liquid’ state. The transition 
between the lamellar gel phase and lamellar liquid-crystalline phase is often 
referred to as ‘melting’. This melting temperature is also known as the transition 
temperature (Tm). 
The greater the transition temperature, the more stable the vesicles would be at 
higher temperatures. This can be applied to the vesicles being investigated in this 
study. Previous studies have been conducted using DMPC as the bulk lipid with 
transition temperature being 23˚C, much lower than the testing temperature 
(37˚C)94. As a result, lipids with higher transition temperatures (DPPC, DHPC and 












1.4. Aims and Objectives  
 
The overall aim of this project was to develop a wound dressing which 
incorporates a pathogenic bacterial toxin sensing element as well as an element for 
enhancing wound healing for the management of paediatric burns.  
The primary objective of this research was to improve the pre-existing bacterial 
sensor component. The pre-existing sensor consisted of mainly DMPC and TCDA s 
showing response to pathogenic bacteria and minimal stability. This system was 
improved through altering the composition of the sensor element as well as 
incorporation of various other stabilising agents.  
On successful improvement of the sensor, the secondary objective was to 
incorporate the phospholipid based sensors were incorporated into  a hydrogel 
matrix, where a range of gels were screened to identify the optimum gel 
composition with minimum interference to the action of the sensor whist 
protecting and retaining hydrated environment.  
The final objective was to produce a prototype dressing, with the capability of 
sensing the presence of pathogenic bacteria. Vesicles were embedded in a hydrogel 
matrix to produce gel-block type prototype as well as a gel-coated fabric prototype 
which used non-woven polypropylene as a scaffold. A final collagen I coating was 
used to add a wound healing enhancement element to the prototype. Individual 
components of the end prototype were tested for their cytotoxic activity using 
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2. Chapter Two: Materials, methods 








2.1. Fluorescence  
 
The use of fluorescence has broadened extensively, not only in fluorescence 
spectroscopy and time resolved fluorescence but also in application for biological 
sciences.  Its use has been extended to environmental monitoring as well as genetic 
analysis and DNA sequencing1. 
Fluorescence is one of two categories of luminescence. Luminescence is the 
emission of light from a substance from an electronically excited state. Depending 
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on the nature of the excited state, the luminescence can be divided into the two 
categories, fluorescence and phosphorescence1.  
 
2.1.1. Principals of fluorescence and phosphorescence 
Fluorescence and phosphorescence, as described above, can be defined as being 
the emission of light by a substance that has absorbed energy through a light 
source or other electromagnetic radiation.  
Fluorescence involves the transitions of electrons from an electronically excited 
state to the ground state. In a singlet exited state the excited electron has the 
opposite spin to the electron on the ground state orbital, therefore the transition is 
spin allowed.  As a result, the transition occurs rapidly. The Jablonski diagram 
(figure 2.1) shows the difference pathways of electrons when excited and relaxed 
due to absorption and emission of energy.  
 
Figure 2.1: The Jablonski diagram, illustrating the excitation of a fluophore to the 
higher energy level and emission of fluorescence and phosphorescence as the 
fluophore moves back down to the ground state. 
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The Jablonski diagram above illustrates the process which occurs between 
absorption and emission of light. The diagram displays different electronic states, 
the singlet (S) and the triplet (T).  In a singlet state, all of the electrons in the 
molecules have paired electrons and in a triplet state, only one set of electrons is 
unpaired. At room temperature, all electrons are assumed to be at the lowest 
energy level, the ground state (0).  
When light energy is absorbed by a fluorophore, the electron is excited to a higher 
vibrational level of a higher state (S1 or S2) from the ground state (S0). 
Fluorescence is the energy emitted when the excited fluorophore is relaxed back to 
its original ground state (S0) from the excited state. The timescale of this process is 
approximately 10 12 s -1 
Phosphorescence is the emission of light from a triplet-excited state. In this case 
the electron of the higher excited state has the same spin as the electron on the 
ground state, therefore transitions are forbidden, which slows down the rate of 
emission. 
 
2.1.3. Stokes Shift (mirror image) 
The absorption spectrum of the fluorophore is often the mirror image of the 
emission spectrum. This is due to reasons described by the Franck-Condon 
principle, which states that the electronic transitions are vertical and do not affect 
distances, which in turn means that the nucleus does not move and thus the 
vibrational levels of the excited state resemble the vibrational state of the ground 





Figure 2.2.: Spectra illustrating the Stokes’ shift. Acknowledgement: J. Zhou Ph.D. 
Thesis 2011. 
 
2.1.4. Fluorescence quenching  
The fluorescence intensity can be reduced by a number of processes, of which 
quenching is one. The energy that has been absorbed can be dissipated, without 
any occurrence of fluorescence. This process can occur though a number of 
mechanisms.  An excited – state fluorophore can be deactivated though contact 
with other molecules within the solution, this type of molecule is called a quencher 
and the process is called collisional quenching. The quencher can bind to the 
fluorophore to form a non-fluorenscent complex; this process is called static 




       [ ]          [ ]    (1) 
Where Fo is the unquenched fluorophore, F is the fluorophore, Ksv is the Stern-
Volmer quenching constant, KQ is the bimolecular quenching rate coefficient, τo is 
the unquenched lifetime.  
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If the quencher forms a non-fluorescent complex when associated with the 
fluophore, static quenching is achieved can be achieved. This can be described by 
deriving the above equation (1).the derived equation (2) is displayed below, where 




      [ ] (2) 
The equations below represent the rate relating the process of fluorescence 
quenching.  A is the fluorophore, A* is the fluorophore in its excited state and kQ 
represents the quenching rate constant. 
A + hυ → A* Rate = ka [A] 
A* → A + hυ Rate = kf [A*] 
A* + Q → A + Q* Rate = kQ [A*] [Q] 
Under steady state: [  ]   
   [ ]
        [ ]
 
The intensity of fluorescence in the absence and the presence of the quencher are 
given below;  
 If (0) = ka [A] Absence of quencher 
  
 If (Q) = kf [A*] 
Presence of 
quencher 
Combining the two equations gives rise to the resulting equation; 
 
      
      
    
  
  
 [ ]  
Plotting of If (0) / If (Q) versus [Q] gives a linear relationship, where the gradient is 
equal to Stern-Volmer constant Ksv, hence; 




This principal of fluorescence and fluorescence quenching was used within this 
project as the signalling indicator of stable vesicles and responsive vesicles. This 
system was also used as the signalling device of the prototype dressing developed.  
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2.1.5. 6(5)- Carboxyfluorescein 
 
 
Figure 2.3:  Showing excitation and emissionspectrum of 6(5)- Carboxyfluorescein, 
indicating excitation wavelength of 480nm and emission wavelength of 530nm 
(left), and the chemical structure of 6(5)- Carboxyfluorescein (right)2 
 
6(5)- Carboxyfluorescein is the fluoresce marker used throughout this project. It is 
one of the most commonly used fluorescence marker used to assess leakage and 
stability of vesicles. The excitation and emission profile (figure2.3) indicates that it 
can be excited at 480nm and the emission wavelength is at 530nm. 6(5)- 
Carboxyfluorescein is a molecule that dimerises at high concentrations, which 










Figure 2.4:  A: The colour change observed in solution as the concentration of 
6(5)- Carboxyfluorescein is increased under white-light. B: The colour change 
observed in solution as the concentration of 6(5)- Carboxyfluorescein is increased 
under UV-light. C: A plot of the self-quenching effect as the concentration of 6(5)- 
Carboxyfluorescein  is increased. Images and graph acknowledgement: W.D. 
Jamieson, Ph.D. Thesis 2013, University of Bath. 
 
From the results of the colour profile associated with the concentration of 6(5)- 
Carboxyfluorescein, a 50mM concentration was thought to give rise to a quenched 










2.1.6. Fluorescence spectroscopy 
A fluorometer is an instrument that measures the parameters of fluorescence: its 
intensity and wavelength distribution of emission spectrum after excitation by a 
specific spectrum of light3. The sample is irradiated by monochromatic light of a 
defined wavelength emitted by a laser lamp. The fluorophore in the sample are 
exited and the emission of fluorescence is detected and recorded as the intensity 
versus the wavelength, as emission spectra1.  The measurements acquired cannot 
be associated with absolute units; as a result the units involved were depicted as 
arbitrary units (au).  
The spectrometer used in this work is a FLUOstar Omega microplate reader 
supplied by BMG labtech ltd. The plate reader covers a wide range of excitation 
and emission wavelengths.  The increase in fluorescence intensity was measured 
to determine vesicle lysis using this instrument. For fluorescence intensity 
measures of vesicles , excitation and emission filters of 485 ± 12 nm and 520 nm 
were used, with a gain of 650.  
The instrument was used for both fluorescence and UV/Vis absorbance 
microscopy.  UV/Vis absorbance was used to follow bacterial growth during the 
study of vesicle response to whole bacteria. These measurements were carried out 





2.2. Microscopy  
Microscopy was used to capture images of vesicles immobilised on surfaces and in 
gel matrixes. Fluorescence microscopy as well as light microscopy was used to 
capture images of cell growth, as well as gel dispersion, on tissue culture plates in 
media containing vesicles.  
 
2.2.1. Bright-field microscopy 
Bright-field microscopy has been used for a number of years to view cells using 
visible light to illuminate a sample on a stage. The image can be magnified up to 
1000 times by the objective lenses. This technique is often used during eukaryotic 
cell culture techniques to obtain cell counts for calculating cell densities and 
viewing the general health of a culture. This methodology was used for basic cell 
culture work as well as viewing cell attachment on prototype dressings, prior to 
more quantitative assessments.  
 
2.2.2. Fluorescence microscopy 
 
Figure 2.5: Schematic of light microscope. Image Acknowledgment: J.Zhou, Ph.D. 
Thesis 2011, University of Bath. 
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Light microscopy can be adapted to use fluorescence in order to give a visual 
representation of fluorescent vesicles, and fluorescently tagged and stained 
samples.  Fluorescence microscopy uses an ultraviolet light source to excite 
fluorophores - the emitted photons can then be detected and viewed optically. In 
the case of inverted microscopes, the light source is passed through the objective 
and onto the sample. The emitted light from the fluorescence of the sample is 
focused by the same objective used as that used for the initial excitation. The light 
is then passed through a filter, to screen out the excitation light, before it passes 
through to the detector4.  This method was used to image vesicles in solution as 
well as vesicles immobilized on a surface.  
A Nikon eclipse TE2000-S epi-fluorescence microscope was used to view vesicles 
in solution and immobilised on glass surface before and after lysis of vesicles by 
Triton X100 and bacterial supernatant. The method was also used to view vesicle 
interaction with eukaryotic cell lines.  
 
2.2.3. Confocal microscopy  
Confocal Microscopy uses similar principals to the conventional fluorescence 
microscopy, but allows imaging in three dimensions. The sample can be scanned in 
the x, y and z direction.  
Two different confocal microscope systems were used within this study. For the 
analysis involving interaction of eukaryotic cells with vesicles, a Nikon A1-R 
Microscope, equipped with a 488 nm DAPI laser and a 10x CFI Plan Fluor DL 
objective, was used. And for analysis of vesicles in gel, the images were acquired 
using a Leica SP3 AOBS confocal. Samples were excited at 488nm and collected at 
504-548nm. The time course was acquired with a 30 second cycle time. Post-




2.2.4. Atomic Force Microscopy (AFM) 
The atomic force microscope was developed in 1986, in order to image the surface 
morphology of a wide range of materials. This type of microscopy enables the 
atomic scale feature detection of polymers, ceramic materials as well as biological 
samples. Atomic force microscopy involves the use of a tip which is moved along 
the sample in the x, y and z direction and either the repulsive force between the tip 
and the sample, or the tip deflection is recorded and converted into an image 
representing the surface of the sample5. There are two main modes: contact and 
tapping mode. The contact mode involves dragging the tip along the sample and 
measuring the forces between the tip and the surface; the tapping mode involves 
using an oscillating tip which oscillates along the surface of the material. As the tip 
oscillates along the surface, it experiences the attractive and repulsive forces. A 
laser beam aimed at the back of the assembly of the tip is reflected off the surface 
to a split photodiode. This detects the small deflections and generated as a 
topographical image  representing the surface structure6.  
A digital Instruments Nanoscope IIIA AFM was used for visualisation of vesicles on 




2.3. Other Instrument types used  
2.3.1. Nanoslight (NTA) 
 
 
Figure 2.6:  The NTA instrument used to measure the size and stability of 
nanoparticles at different temperatures 
 
Nanosight (Figure 2.6) is a technology that involves the tracking of the Brownian 
motion of individual particles in a liquid suspension of nanoparticles. This motion 
is first captured by a video and analysed by tracking the movement of individual 
particle. This instrument tracks individual particles; therefore, the size and 
intensity of particles can be determined. Hence the number of particles in a given 









2.3.2. Osmometer  
Osmolality is a technique used to measure the number of moles/kg of solvent 
present in a given aqueous solution.  The osmolality can be measured from finding 
the freezing point depression of a sample. The measured freezing point depression 
of a sample can be compared against the measure of pure water to give a value of 
osmotic concentration. Using equation 2.1 below, the osmolality of a given sample 
can be calculated, where   is the osmolality of the sample.  This equation assumes 
that the freezing point of an ideal, undissociated aqueous solution with osmolality 
of 1 osmol/kg is -1.858°C 
   
                    
          
 
 
A Löser Micro-Osmometer Type 15 was used to carry out osmolality 
measurements of vesicles and hydrogel matrices. 50μl samples were measured in 
1mL eppindorf tubes, using deionised H20 to calibrate the instrument. Osmolality 




2.4. Vesicle preparation  
2.4.1.  Materials and equipment  
TritonX-100 (#T8787), 10,12-Tricosadiynoic acid, TCDA (#91445), Cholesterol 
(#C8667), maleic anhydride (#M625), Ethylenediaminetetraacetic acid, EDTA 
(#EDS),  sodium chloride, NaCl (#S7653), 5(6)-Carboxyfluorescein (#21877), 1,2-
Distearoyl-sn-glycero-3-phosphoethanolamine (#P3531), 1,2-Distearoyl-sn-
glycero-3-phosphocholine (#P1138) and gelatine from porcine skin (#271616) 
were obtained from Sigma-Aldrich (UK). 1,2-dimyristoyl-sn-glycero-3-
phosphocholine (#850345P) and 1,2-dimyristoyl-sn-glycero-3-
phosphoethanolamine(#850745P), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine 
(#850355), 1,2-dihexadecanoyl-sn-glycero-3-phosphoethanolamine (#110633) 
and 1,2-bis(10,12-tricosadiynoyl)-sn-glycero-3-phosphocholine (#870016)  were 
obtained from Avanti Polar Lipids (USA). Sephadex™ G25 columns were obtained 
from GE Healthcare (UK).  FLUOstar Omega plate reader was purchased from BMG 




2.4.2. Preparation of aqueous solutions 
2.4.2.1. Preparation of HEPES buffer solution (pH 7.4) 
HEPES buffer was prepared at a pH of 7.4 and was used for cleaning of equipment 
and in the purification step of vesicles. The table below shows the composition of 
the buffer solution (Table 2.1) 
Table 2.1: All of the components in the table above were dissolved in 100mL of 




NaCl 107 624 
NaOH 5.6 22.4 
HEPES 10 238.3 
EDTA 1 29.22 
 
 
2.4.2.2. Preparation of Carboxyfluorescein solution (pH 7.4) 
Self-quenched carboxyfluorescein solution was used as the signalling dye 
encapsulated inside the vesicles. The table below shows the components of the dye 
solution (Table2.2). 
Table 2.2: The components shown in the table 2.1 were dissolved in 13mL of 
purified MiliQ water, and the pH was measured and adjusted to pH 7.4. Then the 




NaCl 10 7.6 
NaOH 135 70.2 
HEPES 10 31 
EDTA 1 3.7 
Carboxyfluorescein 50 244 
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2.4.3. Lipid stock preparation  
Two different types of lipid stock solutions were made. Stock 1 solution consisted 
of each of the lipid components dissolved in 1mL of Chloroform at a concentration 
of 0.01mM. The lipid stock 2 solutions were then made using different percentage 
concentrations of each lipid stock 1 solutions.  
 
Stock 1: 
Table 2.3: Stock 1 solution, in which each component was dissolved in 1mL of 
chloroform 













Type A: lipid Vesicle 
Table 2.4: Summary of composition of vesicles without crosslinker incorporated. 





Mass (mg) Amount in 
100µL 
(µL) 
DMPE/DPPE/DSPE 73 49.6/53.6/57.7 73 
DMPE/DPPE/DSPE 2 1.28/1.38/1.5 2 
CHO 20 7.8 20 
 
100 µL of the stock 2 solution was dissolved in 1mL of chloroform, in a glass vial. 
The solvent was then evaporated off under nitrogen, until a thin film was formed at 
the bottom of the glass vial. The thin film of lipid was then re-suspended in 5mL of 
CF50 solution and heated to 75° C in a water bath for 10 mins. Once the lipid 
suspension had fully dissolved in CF50 solution, a series of freeze and thaw cycles 
enhanced encapsulation of vesicles. This process was repeated three times. 
Following on from this, the vesicle solution was extruded three times through two 
polycarbonate membranes at the corresponding temperature depending on the 
bulk lipid used and purified using Nap-25 columns. The purified vesicles solution 




Type B: TCDA containing Vesicle Synthesis 
Table 2.5: The components were all dissolved in 1mL of Chloroform. Any variation 





Mass (mg) Amount taken from 
stock solution 1 for 100 
µL of stock solution 2 
(µL) 
TCDA 25 8.75 25 
DMPC/DPPC/DSPC 53 36.0/38.7/41.9 53 
DMPE/DPPE/DSPE 2 1.28/1.38/1.5 2 
CHO 20 7.80 20 
 
Type B vesicles were made following the same method as the lipid vesicles (type 
A), however, the purified vesicle solution was kept at 4 °C overnight and 
crosslinked the next morning using a UV Crosslinker at 254nm7.   
 
Type C: DC8, 9PC containing Vesicle Synthesis 
Table 2.6: A summary of the composition of DC8, 9PC containing vesicles 




Amount taken from 
stock solution 1 for 
100 µL of stock 
solution 2 (µL) 
DC8,9PC 30 26.8 30 
DMPC  40 27.4 40 




Type C vesicles were made using the same method as  the vesicles containing 
TCDA (Type B) apart from the samples being cross-linked immediately following 
purification (and not left at 4°C overnight).  
 
2.4.4. Extrusion  
 
Figure 2.7:  The Liposofast ™® extruder 
 
Following re-suspension of lipid film into the CF50 buffer solution, a series of 
freeze-thaw processes was carried out in order to enhance encapsulation of the 
surrounding solution into the vesicle. This process was then followed by extrusion 
of vesicles through a filter. The extrusion of vesicles was carried out using a 
Liposofast ™® extruder (Figure 2.7) and passed through two 0.1micron 
polycarbonate filters. During this process, the extruder was heated to at least 10°C 
higher than the transition temperature of the lipid 8. The table below shows a 




Table 2.7:  Showing the transition temperature and the extrusion temperature of 
different lipid systems used in this investigation 




DMPC 23 33 
DPPC 45 55 
DSPC 55 65 
 
2.4.5. Purification of vesicles 
The separation of vesicles with un-encapsulated CF50 dye was carried out using 
GE healthcare NAP-25 sephadex columns. The column storage solution was 
drained and equilibrated with excess HEPES buffer. Once the buffer solution had 
passed through the column, 2mL of the sample was loaded on the column. When 
the sample was loaded onto the column, 1mL of HEPES buffer was loaded and left 
to drain. Following this, a further 2mL of the buffer was loaded and the purified 




2.4.6. Photo-polymerisation to crosslink vesicles 
Vesicles containing TCDA were crosslinked using UV light (λ = 254 nm). A 1mL 
aliquot of the vesicle solution was loaded into a 1.4mL quartz cuvette and placed 
into the middle of the UV crosslinker (230V, 30Hz, 254nm), supplied by Ultra 
Violet Products.  The crosslinking of TCDA occurred at timer setting 1 (Approx. 6 
seconds). The crosslinking mechanism is shown by Figure 2.8, section 3.1.6.1. 
displays a more detailed explanation of TCDA stabilisation. 
 
Figure 2.8: Representation of TCDA polymerisation, though UV irradiation. 




2.5. Vesicle characterization methods  
 
Following preparation, vesicles were characterised to ensure initial formation, 
encapsulation of self-quenched dye, the size characterisation as well as uniform of 
distribution particles.  
 
2.5.1. Vesicle characterisation during purification 
Vesicle characterisation during the purification stage was carried out by collecting 
four drops of eluent from the NAP-25 column into each well of a 96 well plate 
(Figure 2.8). The fluorescence intensity was measured using a FLUOstar BMG 
Labtech microplate reader.  
 
2.5.2. Using the NTA system 
 
Figure 2.9: Schematic of the NTA system 
 
Utilising Nanosights’ NTA instrument the Brownian motion of nanoparticles in 
HEPES was measured on a particle-by-particle basis. The sample chamber was 
flushed with the eluent, in this case HEPES, followed by addition of a diluted 
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sample of 100 µL of nanocapsules. This sample was further diluted by altering the 
ratios of sample to eluent composition as required. 
 
2.5.3. Methods for stability tests and solution preparation  
General stability of vesicles was achieved by simple fluorescence measurements 
following addition of Triton X100 or HEPES buffer. A large increase in fluorescence 
upon addition of Triton X100 compared to HEPES buffer indicated stable vesicles. 
This test was performed immediately following formation, purification and in 
some cases crosslinking steps.  
Upon successful formation and completion of the immediate stability test, their 
longer-term stabilities were examined.  Long-term stability studies were 
performed in various different conditions. These include, pH and temperature.   
 
2.5.4. pH stability assay and osmotic pressure measurement.  
HEPES buffer was adjusted to achieve different pH ranging from 4 to 8. This was 
followed by vesicle incubation in the pre-prepared pH adjusted HEPES buffer 
solutions in 96 well plates, at various temperatures.  
 
2.5.5. Temperature stability assay 
Changes to the temperature were achieved by storing in temperature-controlled 
incubators. Test solutions were pipetted onto 96 well plates with water in the out 
wells of the plate. The plates were sealed with masking tape, wrapped in foil and 
placed in zip-lock bags before incubating at set temperature for a period of 14 days, 






2.6. Preparation of bacterial cultures 
2.6.1. Materials and equipment 
LB Broth (#L3022) and Tryptic Soy Broth (#22092) - obtained from Sigma-Aldrich 
(UK). 
Different strains of pathogenic bacteria: P. aeruginosa and Methicillin sensitive S. 
aureus. (MSSA, RN4282, RN6390B, RN6911); and one strain of non-pathogenic 
bacteria: Escherichia coli DH5α, were cultured for the purpose of sensitivity 
studies.  
 
2.6.2. Sterilisation  
Maintaining sterile conditions is essential when working with biological samples. 
All work involving the use of biological samples was conducted in Class II safety 
cabinets, in addition to the use of 70% alcohol solutions or bleach to disinfect the 
surfaces and any containers entering or leaving the cabinet. 
Sterilisation of media and any equipment used in cabinets was conducted by 
autoclave, which uses heat sterilisation. The autoclave system decontaminates 
solutions and equipment at 121°C and 15psi for 15mins9 
 
2.6.3. Principals of bacterial growth  
Bacteria follow the process of binary fission to grow and reproduce in fixed 
proportions. This is a form of asexual reproduction. During the stage of 
reproduction and growth, the temperature and the nutrient available play an 
important role. The temperature for optimal bacterial growth is dependent on the 
strain, with 37°C being the typically used temperature. The type of nutrient 
required is also dependent on the strain, thus different media are used for growth 
of different bacteria. In this study, Tryptic Soy Broth (TSB) was used for all strains 
of S. aureus and Luria Broh (LB) was used for P. aeruginosa and E. coli.  
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In research laboratories, bacterial growth take place on solid agar plates, in 37°C 
incubators to isolate single colonies followed by culture in liquid medium in 37°C 
shaking incubators. Given that mutation does not occur, all cells in the resulting 
culture should be identical to the mother cells of the original colony.  
 
Figure 2.10: The stages of bacterial growth. A: initial lag phase, B: exponential 
growth phase, C: stationary phase, D: logarithmic decline phase. 
 
The population growth of bacteria occurs in several stages. The initial phase is 
termed the lag phase, followed by the exponential log phase in which the increase 
in population density follows a logarithmic pattern. This is then followed by a 
stationary phase in which population increase equals population death, resulting 
in no general increase in population. Finally there is a logarithmic decrease in 
population, where lack of nutrients and space (steric hindrance) results in death10 
(Figure 2.10).  
 
2.6.4. Bacterial culture preparation  
Culturing of P. aeruginosa and E. coli DH5α was carried out in Luria broth (LB). For 
S. aureus it was carried out in Tryptic Soy Broth (TSB). Bacteria obtained from 
stocks were cultured at 37 °C in broth over 18 h (overnight). The 18 h culture was 
diluted to a concentration of 1x106 CFU mL-1. This re-diluted culture was added to 
vesicle solutions, in a 1:1 ratio, after which fluorescence and control absorbance 
measurements were taken over a minimum of 17h.  
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2.6.5. Bacterial supernatant preparation  
500µL of overnight (18h) bacterial cultures were grown in conical flasks 
containing 50mL of corresponding media. These were cultured for a further period 
of 18h. The 2nd overnight cultures were centrifuged twice (5000 rev min-1, 15 min), 
to remove whole bacterial cells and debris. The supernatants were collected, filter-
sterilised through 0.22 µm filters and stored at -20 °C. These supernatants were 
tested against each vesicle type in a 1:1 ratio and fluorescence was monitored over 




2.7. Hydrogel and prototype preparation  
2.7.1. Materials and equipment 
Gelatin (#48723), agarose(#A9529),  hypromellose (#H3785),  agar (#A1296)  
were obtained from Sigma-Aldrich (UK). FmocFF was obtained from BACHEM (UK). 
Components for the polyacrylamide gels were obtained from First Water Ltd. (UK).  
 
2.7.2. Hydrogel preparation  
Preparation of natural hydrogels involved heating and stirring of the buffer 
solution containing gelling agents. Once the gelling agents had dissolved into the 
buffer solution, the formation of these gels occurred during the cooling stages of 
the buffer solutions. 
 
2.7.3. Preparation of natural hydrogel  
A. Gelatin: the HEPES buffer solution containing required amounts of gelatin 
was heated to 60 °C with stirring for 10 mins. The solution containing 
vesicles was added to the warm solution of gel and further stirred to ensure 
uniform distribution of vesicles throughout the gel mixture. The mixture 
was immediately used for further analysis.  
B. Agarose: Agarose gels were prepared in HEPES buffer by microwaving the 
solutions for 3 mins at 850ca. As for the gelatin mixture, vesicles were 
mixed into the warm (around 37°C) gel mixture and used immediately for 
further analysis. 
C. Agar: agar gels were formed by dissolving the appropriate amount of agar 
into HEPES buffer and heating with stirring until a clear solution was 
formed. Vesicles were mixed into the warm gel (around 37°C) and used 
immediately for further analysis.  
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D. Xanthan and guar gum: Different amounts of the gelling agents were 
added to HEPES buffer and heated with stirring until the entire gelling 
agent had dissolved.  
E. Hypromellose: Hypromellose gels were prepared by heating half of the 
required HEPES buffer to 80°C. Followed by addition of hypromellose 
powder with continuous heating and stirring. Finally, once all of the powder 
had dissolved, the solution was continuously stirred but at room 
temperature and the remaining half of the HEPES buffer was added and 
stirred further for at least 30 mins.  The gel was then allowed to form 
overnight before vesicles were added and used for further analysis.  
F. Polyacrylamide hydrogels: the original formulation contained 2.86 mL of 
deionized H2O, 3.57g of glycerol, 3.57g of acrylamide monomer as well a 
mixture of the photo-initiator and crosslinker. Variation of the gel was 
carried out by replacing the water content with HEPES buffer or vesicle 
solution. Preparation of the pre-crosslinked gel mixture involved initial 
stirring of aqueous solutions with glycerol for 5 mins before addition of the 
other components. The solution was stirred for at least 30 mins in the dark, 
before vesicle solutions were added.  
G. FmocFF gel: FmocFF stock solutions were prepared in DMSO and stored at 
-20°C. The ‘solvent-switch’ method was followed with FmocFF stock: water 
ratio of 1μL: 49μL. The gel was allowed to set for 45 mins before any 




2.8. Toxicity assays 
2.8.1. Materials and equipment 
DMEM and DPBS media were purchased from Fischer scientific (UK). Trypsin 
EDTA cell resazurin were obtained from Sigma-Aldrich (UK).  
 
2.8.2. Eukaryotic keratinocyte and fibroblast Cell culture 
HaCaT Cells were grown in Dulbecco’s Modified Eagle Medium (DMEM) with 10% 
fetal bovine serum (FBS) and Penicillin, Streptomycin and Glutamine (PSG) in a 
tissue culture incubator at 37°C and 5% CO2. Cells were revived and grown to 
achieve 70% confluent monolayers of cells in T25 cm3 or T75 cm3 flasks. Once 70% 
confluence was achieved, the cells were washed in PBS and fresh growth media 
was added with vesicles at different concentrations, lysed vesicles at different 
concentrations and controls. 10% Triton X-100 was used as a positive control 
(cytotoxic to cells).  The cells were incubated with the different testing solutions 
for 24, 48 and 72 h.  
 
2.8.3. Resazurin assay 
Following incubation of cells with testing solutions, media was removed from the 
well, washed with PBS and 500µL of 10% resazurin solution in cell growth media 
was added to each well. The plate was further incubated for 2 h at 37°C and 5% 
CO2 
.  
Figure 2.11: Structure of A resazurin and B resorufin11. 
 
A     B 
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Resazurin (A) can be reduced to form resorufin (B), with a change of colour from 
deep blue to pink. The mechanism of the transfer from resazurin to resorufin by 
eukaryotic cells is thought to involve the reduction of NADH12. NADH is an 
important biochemical vector used to indicate the viability of cells13.  
NADH + A + H+                 NAD+ + B + H20                   (1) 
Equation (1) shows the proposed reaction scheme of reduction of resazurin by 
NADH to yield resorufin and NAD+ 
The fluorescence of resazurin was measured using a BMG LAB tech micro plate 
reader.  Excitation and emission filters of 544 nm and 590 nm were used for 




2.9. Prototype preparation methods  
2.9.1. Materials and equipment 
Non-woven polypropylene fabric was obtained from Boots Pharmacy, Collagen I 
was obtained from Invitrogen, and plastic backing sheets were obtained from 
Mölnlycke Health Care (Sweden). 
 
2.9.2. Gel-block system 
 
 
Figure 2.12: Representation of gel block system 
 
Gel-block systems were prepared by loading 500µL of 1:2 ratio of vesicle to gel 
mixtures into each well of 12 well plates. The gels were then allowed to set at 4°C 
for a minimum of 30 mins. The prototypes were stored at 4°C and discarded 




2.9.3. Gel coated fabric    
Non-woven polypropelene fabric was cut to 2cm in diameter circular fragments, 
washed in ethanol, dried and further washed in HEPES buffer (x2). The wet-in-
HEPES pieces of fabric were dip coated, twice, in a 1:2 ratio of vesicle to gel 
mixture before storing at 4°C. The gel coated fabric prototypes were also discarded 
when exceeding 2 days of storage without use. For experimental analysis, two 
layers of the coated fabric were used per well of a 12 well plate (Figure 2.13). 
 
Figure 2.13: Diagrammatic representation of prototype layout in each well of a 12 
well plate, with two layers of coated fabric 
 
 
2.9.4. Collagen coated prototype 
The collagen coated prototypes followed the same preparation method as for the 
gel-coated prototype, with an additional coating in 1% collagen solution following 
two dips in the vesicle/gel mixture.  
 
2.9.5. Stability and sensitivity assay  
Overnight stability assays were carried out by overnight incubation of gel-blocks 
with HEPES buffer and Triton as a control. Fluorescence measurements were 
carried out by well scan analysis using the fluorometer described in section 2.1.6. 
Backing 




Sensitivity assays were carried out using overnight bacterial culture as well as 
bacterial supernatant. However, as previous results demonstrated that bacterial 
supernatants showed sufficient response for the purpose of this study, supernatant 
studies were the preferred option for sensitivity analysis.  
For assays using overnight bacterial culture, 1mL of overnight culture with cell 
density of 1x106 CFU/mL was used. For assays using supernatant, 500µL of 
bacterial supernatant was used.   
 
2.9.6. Fluorescence reading 
The stability and sensitivity analysis of prototype dressings were carried out by 
measuring fluorescence intensity. Prototypes were made in 12 or 24 well plates 
and 10x10 well scan measurements were taken rather than single point scans 
taken when using 96well plates. This was done in order to obtain accurate 
fluorescence readings of vesicles that may be unevenly distributed.   
 
2.9.7. Analysis of fluorescence results 
An average of the well scan was calculated using the values obtain from the middle 
of the well (figure 2.14). The values selected in the red box on Figure 2.14 were 
used to calculate the average well scan values. 
 
Figure 2.14: Representation of well scan. The values indicated by the red box were 




2.9.8. Cell attachment assays  
1mL of media containing cell density of 2x105 cells mL-1 was loaded onto each well. 
The wells were pre-loaded with a gel to stop migration of cells onto the surface of 
the tissue culture well plate (apart from the positive control where the cells were 
grown on the surface of the tissue culture well plate) as well as the collagen coated 
dressings and the agarose dressings placed into each well. The cells were allowed 
to proliferate onto the surfaces for 30 mins. The solution was then removed, wells 
were carefully washed with PBS and 1mL of tissue culture media was replenished. 
The cells were then incubated at 37°C and 5% CO2 for 48h. 
Following 48h incubation, the media was removed and the wells were washed 
with PBS. Rezasurin assay was carried out to assess cell viability. 500µL of 
resazurin assay solution (10% resazurin in tissue culture media) was added into 
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3.1. Introduction to vesicle optimisation  
 
In this chapter, the different types of vesicles designed for optimal stability and 
sensitivity to bacterial toxins will be addressed. Numerous types of vesicles were 
designed and tested for their stability in different pH buffers, biological media, as 
well as across a range of temperatures. Along with their stability, their sensitivity 
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to bacterial supernatant was screened, and the vesicle with the optimum stability 
as well as sensitivity was chosen as the candidate for further development.  
 
3.1.1. Vesicle naming convention 
Vesicles were named according to the stabilising agents utilised along with their 
percentage by volume, followed by the bulk lipid found within the vesicle. For 
example, vesicles using a 10% volume of 10,12-Tricosadiynoic acid (TCDA) with a 
mixture of 20% cholesterol, 2% DPPE and 68% DPPC were named 10% TCDA-DP. 
 
3.1.2. Defining vesicle stability  
Vesicle stability can be categorized into three classes: initial stability, short -term 
stability and long-term stability. The initial stability is the stable formation of 
vesicles, following the stages of purification with NAP- 25 column and crosslinking 
of the relevant stabilising agents. The short term stability is the stability of vesicles 
during an overnight study run at 37°C. The long term stability indicates stability of 
vesicles over a period of 14 days at given temperature or pH.  
 
3.1.3.  The Stability-response parameter  
The stability response parameter was used to convert the arbitrary fluorescence 
values to values which can be used to compare different vesicles types. The 
stability-response parameter of the vesicles was calculated using the following 
parameter:  
 
                                      
  
  
                     
Where Fi is the initial vesicle fluorescence value and Ff is the final vesicle 
fluorescence value following completion of a given study. For stability assays, Ff is 
the final vesicle fluorescence after addition of lytic agent following a full stability 
study. The addition of the surfactant Triton X-100TM, giving rise to total vesicle 
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disruption, was considered to deliver the maximum fluorescence obtainable. For 
short-term stability assays, Fi is the initial fluorescence value prior to conducting 
any studies. For long-term stability assays, Fi is the fluorescence value obtained 
following incubation for 14 days. For overnight assays, Fi is the fluorescence before 
addition of test solution for overnight incubation and Ff is the fluorescence 
following overnight incubation. 
 
3.1.4. Stability issues  
In order for these vesicles to be used as bacterial sensors immobilised in dressings, 
certain stability criteria have to be met. So as to prevent false positives, vesicles 
had to demonstrate stability with respect to factors such as temperature, pH, 
dehydration as well as biological components such as inflammatory responses of 
the human body, eukaryotic cells, exudate and wound fluid.   
As discussed previously, the most common form of uniformLy distributed vesicles 
is a large unilamellar vesicle. These are relatively stable in solution; however 
stability is largely dependent on the type as well as the combination of lipids used. 
The majority of research on utilising vesicles as vehicles of active ingredients has 
been focused on producing vesicles that are stable in solution until the target site is 
reached. Numerous methods were investigated in order to achieve the desired 
stability, including coating vesicles with protective nanoparticles, coating vesicles 
in gels and using stabilizing agents.    
Controlling lysis such that it only occurs upon a specified environmental trigger is 
central to achieving targeted delivery. In order to accomplish this goal, maintaining 
the vesicle stability in a wide range of temperatures and pHs is essential. 
Accomplishing and maintaining vesicle stability at 37°C (human normal body 
temperature), was one of the major requirements within this study, thus the 




3.1.5. Thermal stability  
The thermal stability of vesicles in this study is closely related to the lamellar 
phase transition temperature of the core lipids. As mentioned in Chapter 1, 
transition temperature refers to the temperature required for transition of the 
lipid bilayer between gel and liquid-crystalline states. This transition involves van 
der Waals forces between adjacent fatty acid chains. As a result, the longer the 
chain, the higher the temperature required to disrupt the interaction between the 
chains.  
 
Figure 0.1: Representation of the transition temperatures of various lipids. The 
peak of each curve indicates the ‘melting temperature’ of the lipids from gel to 
liquid- crystalline states. The plot indicates that as the lipid chain length increases, 
the transition temperature increases1. 
 
The temperature stability at each phase varies, subject to the hydrocarbon chain 
length of the lipid.. This is due to the increase in interactions between the 
hydrocarbon chains as the chain length increases, indicating an increase in van der 
Waals forces between the chains. Figure 3.1 shows the relationship between the 




3.1.6. Stabilising agents 
Various methods of vesicle stabilization for targeted drug delivery and triggered 
release of vesicles have been explored in the literature. An example of this would 
be incorporation of polyethylene glycol (PEG) lipids.  
Furthermore, previous research conducted by the group showed that stabilisation 
was achieved by incorporation of photo-polymerisable components, introducing 
localized cross-linked areas within the vesicle system, inducing stability.  
There is evidence in the literature that various different methods have been 
explored to ensure stability of vesicles. Modification of lipid bilayer using mixed 
lipid mixtures is one of the most looked at areas of stabilization. Formation of 
‘stealth liposomes’ can be achieved by addition of PEGylated lipid is a large area of 
showing prolonged blood circulation time. 
Previous research conducted by the group involved the use of photo-polymerisable 
fatty acids, such as polydiacetylenes. Polydiacetylenes such as 10,12- 
Tricosadynoic acids have a hydrophilic head group and a hydrophobic tail group, 
thus can be easily incorporated into lipid membrane bilayers. The stabilizing 
mechanism is not fully understood, however upon photo-polymerisation at 254nm, 
stability of DMPC vesicles was shown to improve.  
 
3.1.6.1. Polydiacetylenes stabilized vesicles 
The use polydiacetylenes (PDA) such as 10,12-Tricosadiynoic acid (TCDA), in lipid 
membranes was first shown by Kolusheva et al. in 20002. TCDA is a 
polydiacetylenes molecule (see figure 3.2 below), which can self- assemble due to 
its amphiphilic nature, consisting of polar head group and a hydrophilic tail 
containing a diacetylene moiety.  These monomers can be polymerised by UV 





Figure 0.2: Structure of 10,12-Tricosadiynoic acid (TCDA) 
 
TCDA goes through a colour transition from blue to red, following incorporation 
into lipid bilayers or the colour change can also be induced by an external stimuli 
such as heat, association with organic solvent, UV light as well as mechanical  
stress. The colour profiles associated with incorporation of difference 
concentrations of TCDA is shown by diagram A of Figure 3.3.  
   
 
Figure 0.3. A Representing the colour profiles associated with different dilutions 
of TCDA. As well as representation of TCDA crosslinking, initiated by formation of 
radicals of B irradiated TCDA to from the polymerised product. Acknowledgment 






The highly ordered TCDA can be potopholimersed by irradiation with 254 nm UV. 
A free radical initiated chain reaction initiates the polymerisation. When these 
diacetylene moiety-containing monomers are incorporated into lipid vesicles and 
polymerised, this gives rise to polydiacetylene vesicles, vesicles with rigid regions, 
forming stable/destabilized vesicles5.   
The incorporation of TCDA into lipid mixtures and formation of stabilised vesicles 
for development of bacterial toxin sensitive vesicles was researched and reported 
by Zhou et al6. Within this project, the concept introduced by Zhou et al. was 
further elaborated to develop further stabilised and sensitive vesicle systems.  
 
3.1.6.1. DC8,9PC stabilized vesicles  
1,2-bis(tricosa-10,12-diynoil)-sn-glycero-3-phosphocholine (DC8,9PC) is a photo-
polymerisable lipid with highly reactive diacetylene groups, which can be photo-
polymerised to create polymerised regions7,8. The miscibility of DC8,9PC with 
other lipids were shown by previous studies, demonstrating the potential of 
DC8,9PCs in stabilisation of lipid vesicles in a similar manner to TCDA.  
 
 
Figure 0.4:  Chemical structure of 1,2-bis(10,12-tricosadiynoyl)-sn-glycero-3-
phosphocholine, (DC8,9PC) 
 
3.1.6.2. PEG stabilization 
Stealth liposomes are the term used to describe the group of vesicles stabilised 
using PEG. PEG–lipids have a polyethylene glycol chain on the headgroup of a 
phospholipid, which can be incorporated into lipid mixtures and subsequently 
giving rise to liposomes. An example of a developed pegylated liposomal carrier 
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would be Dox-NP, in which the peg-stabilised liposome acts as a drug carrier for 
cancer therapy9.  
  
3.1.7. Sensitivity of vesicles  
As well as exhibiting appropriate stability, the vesicles need to be sensitive to their 
trigger, which in this case are bacterial membrane damaging proteins. One of the 
ways of ensuring sensitivity is by creating a system which resembles eukaryotic 
cells. Membrane damaging toxins often require cholesterol to bind to the surface of 
the membrane. In addition to cholesterol, membrane fluidity is thought to be 
important in tuning the sensitivity of vesicles to bacterial proteins10.  
3.1.7.1. Membrane fluidity  
Membrane fluidity is closely related to the packing efficiency of lipid fatty acid 
chains. In a liquid-crystalline state, the hydrocarbon chains of the phospholipids 
are in constant motion and fully disordered, this occurs at higher temperature. As 
the temperature is decreased, hydrocarbon chains extend and the fatty acid chains 
become highly ordered, and van der Waals interactions hold the chains closely 
packed. This is called the gel-crystalline state (Figure 3.5). The temperature at 
which this change in state occurs is the phase transition temperature, Tm, 
previously referred to in Chapter 1.  
 
                   
 
Figure 0.5: the transitions between liquid-crystalline and gel-crystalline phase of a 
lipid bilayer 
 
Liquid-Crystalline   Gel-Crystalline 
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For a lipid bilayer to demonstrate sensitivity to bacterial toxins, a liquid-crystalline 
phase of the lipid bilayer is preferred over the gel-crystalline phase, due to the 
rigidity of the gel-crystalline phase interfering with the action of bacterial toxins.  
3.1.7.2. Addition of Cholesterol  
 
 
Figure 0.6: Structure of cholesterol 
 
Cholesterol is an important and vital constituent of cell membranes. It is mostly 
hydrophobic but has a polar hydroxyl group, which allows the molecule to be 
amphipathic and can thus be inserted into a lipid bilayer (Figure 3.6). Cholesterol 
causes the phospholipid molecule to be in an ‘intermediate state’, and interferes 
with the close packing of the fatty acid chains. It increases the fluidity of the 
hydrocarbon chain below the gel-to-liquid crystalline phase and decreases the 
fluidity above the gel-liquid crystalline phase11. This has a ‘destabilising ‘effect on 
lipid bilayers, causing it to be close to a gel-crystalline phase, enabling the lipid 
bilayer to be more sensitive to bacterial toxins. Cholesterol makes up 
approximately 20% of the cell membrane. As a result, a 20% cholesterol 








3.2. Vesicle formation and characterisation 
 
Vesicle preparation methods and list of vesicle compositions can be found in 
Chapter two of this document. Vesicle formation and characterisation was 
achieved using various visual and analytical techniques, during and after formation 
and purification of vesicles.  
During the stages of vesicle preparation, vesicle formation was visually observed 
by the change in transparency of the lipid-containing solution mixture. This is 
illustrated in figure 3.7 where there is a clearly visible change in appearance of the 
solution before (A) and after extrusion (B).  
 
                 
 
Figure 0.7: A. Aqueous solution containing lipid mixture: opaque before extrusion 




3.2.6. Vesicle characterisation during purification 
Vesicles were characterised at the purification stage. In Figure 3.7 a plot of the 
fluorescence intensity vs. eluent volume shows two peaks, of which the peak with 
the lower maximum intensity represents self-quenched fluorescence of dye 
encapsulated in vesicles, and the peak with the higher maximum intensity 
represents un-quenched fluorescence of free-flowing dye.  
 
Figure 0.8: Fluorescence intensity of eluent using NAP-25 column. 
Acknowledgment: Jessica Bean Ph.D. candidate, Department of Chemistry, 
University of Bath. 
 
The portion of the eluent solution containing vesicles, highlighted in green in figure 




3.2.7. Vesicle size characterisation 
The Nanoparticle Tracking Analysis (NTA) was used to determine the size of the 25% 
TCDA- DP vesicle system, as well as determining the number of particles in a given 
volume of solution (Figure 3.9).  
 
Figure 0.9: A. Plot of the size and population of DPPC vesicles in HEPES (red) and 
in Triton solution (orange). The decrease in population of 100nm vesicles is clearly 
visible, as the detergent is introduced. B. Showing the capture of the video taken 
for analysis of vesicles in HEPES. C. Showing the capture of the video taken for 
analysis of vesicles on addition of Triton. 
 
The NTA shows a peak at 100nm, indicating the presence of 100nm vesicles when 
diluted in HEPES and on addition of Triton X-100, this peak disappears, and 
indicating absence of 100nm vesicles. This suggests that Triton X-100 successfully 
lyses vesicles.  The NTA also showed that vesicle concentration could be 





3.2.8. Vesicle characterisation by microscopy  
Further vesicle characterisation was carried out with the use of Atomic Force 
Microscopy (AFM). Vesicles were immobilised, by covalent bonding, onto maleic 
anhydride coated glass slides. Maleic anhydride coating of glass slides was 
achieved by means of plasma polymerisation. The AFM images below (Figure3.10) 
show vesicle attachment on the modified glass slides. A uniform distribution of 
vesicles can be observed with approximately 100nm in size.  This is consistent 
with the size of vesicles expected to form through extrusion, confirming that the 
extruded size is the size of the end product.  
 
-               
Figure 0.10: AFM of vesicles on Maleic anhydride coated glass slides. A. shows a 
forward amplitude scan zoomed in at frame size of 5µm. B. shows a backwards 
Topography scan zoomed at frame size of 254nm. 
 
3.2.9. Summary of vesicle characterisation 
Formation of uniform sized vesicles was achieved by means of a solvent 
evaporation method followed by extrusion through membranes with a pore size of 
100 nm. Various characterisation methods were used to successfully detect the 
presence of vesicles with encapsulated self-quenched carboxyfluorescein. On 
further analysis, the size of the vesicles was confidently identified by means of 









































































3.3. Vesicle stabilisation using ‘stabilising agents’ 
 
Vesicles incorporating different types of stabilising agents were prepared and 
tested to discover the ‘ideal’ vesicle composition that exhibited appropriate 
stability as well as sensitivity to bacterial supernatant.  
 
3.3.6. Incorporation of stabilizing agents in DMPC vesicles 
As referred to in Section 3.1, previous research conducted by the group 
demonstrated that adding TCDA into the vesicle membrane improved the stability 
of DMPC vesicles. Following on from these results, various different methods were 
used to attempt to further improve the general stability of DMPC vesicles, using 
stabilizing agents such as DC8,9PC, PEG lipids and TCDA.  
 
3.3.7. TCDA stabilised vesicles 
Varying concentrations of TCDA were incorporated into DMPC vesicles containing 
cholesterol and DMPE. The short-term stability of the vesicles in HEPES was 
studied overnight, as well as sensitivity to a lytic agent with Triton X-100 as a 








Figure 0.11: Stability measurements of TCDA-DM systems with varying 




Figure 0.12: Toxin tests on vesicles with TCDA concentrations varying from 0% to 
40%.; illustrating the optimum TCDA concentration (high sensitivity and stability) 
may be between 20% and 30%. Study performed by J. Zhou, University of Bath. 
 
The two plots above (figures 3.11 and 3.12) indicate that the optimum balance 
between stability and sensitivity lies between TCDA concentrations of 20 and 30%. 
An in-depth study, summarised in figure 3.12, shows the response of 20, 25 and 30% 
TCDA-DM systems. The results were translated to show SR-parameter values in 






























































































Figure 0.13: Effect of TCDA concentration on sensitivity of DMPC vesicles to 
purified toxins. Fluorescence intensity values were converted to SR-parameter 
values to aid analysis of results 
 
 
Figure 0.14:  Effect of TCDA concentration on sensitivity of DMPC to bacterial 
supernatant. Fluorescence intensity values were converted to SR-parameter values 











































































































































Using the data summarised in figures 3.13 and 3.14, the optimum concentration of 
TCDA in a DMPC system was concluded to be 25% TCDA. A vesicle containing 25% 
TCDA-DM was shown to have improved stability overnight at 37°C in HEPES, 
compared to the 20% TCDA-DM system. When comparing the 25 and 30% TCDA-
DM systems, the 25% TCDA-DM system was shown to be more stable and sensitive. 
This result was rather contradictory to the trend observed by J. Zhou, of increasing 
stability with an increase in TCDA. The result was confirmed by numerous repeats, 
indicating an optimum stability and sensitivity was achieved at 25% TCDA of the 
DMPC lipid mixture.  
 
3.3.8. Studying the stabilizing effects of DC8,9PC in DMPC vesicles 
DMPC vesicles containing various percentages (ranging from 0 to 100%) of 
DC8,9PC, were formulated. In contrast to reported results, DC8,9PC incorporated 
vesicles showed limited stability, and no improvement in stability was observed 
compared to TCDA incorporated vesicles. Upon overnight storage an increase in 
fluorescence intensity was observed, probably due to passive leakage.  
 
3.3.9. Studies of the stabilizing effects of PEG lipids in DMPC vesicles 
Varying concentrations of PEG 550- and PEG1000-containing DMPC-based lipid 
vesicles were formulated. Vesicles incorporating PEG 550 failed to form; there was 
an absence of the first fluorescence peak observed during the purification process.  
Vesicles incorporating PEG1000 exhibited increased fluorescence following 
storage. This maybe have been due to formation of unstable vesicles, increased 
passive leakage of encapsulated dye due to increased fluidity of membrane, as well 
as delayed release of un-encapsulated dye entrapped within the highly entangled 
long PEG head group.  
As a result PEG stabilised vesicles exhibited no improvement in stability when 
compared to the TCDA-DM system. These results have been tabulated along with 
other vesicle types in Section 3.5 of this Chapter.  
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3.4. Vesicle stabilisation by increasing lipid chain length   
 
Further vesicle stabilisation studies were carried out with respect to increasing the 
lipid chain length of the bulk lipid, with the intention of improving stability with 
increasing transition temperature. These were carried out using DPPC (C16) and 
DSPC (C18) in the place of DMPC (C14) as the bulk lipid.  
 
3.4.6. Studying the effect on stability of changing the phospholipid 
chain length of TCDA containing vesicles  
Two samples of 25% TCDA vesicles were prepared using DMPC as the bulk lipid 
and DPPC as the bulk lipid, respectively. Vesicle stability was compared by 
incubation at 37°C in a 96 well plate overnight, and their SR-parameters were 







Figure 0.15: SR-parameters calculated following overnight incubation at 37°C. The 
SR-parameter of the 25% TCDA-DP system is more than double that of the 25% 
TCDA-DM system, indicating improved stability by incorporation of TCDA in place 
of the DMPC in the DPPC system. 
 
The SR-parameter of the 25% TCDA-DP system was shown to be more than double 
that of the 25% TCDA-DM system. This indicates that increasing the bulk lipid 

























3.4.7. Studying the effect of changing phospholipid chain length of
  TCDA-containing vesicles, on their sensitivity to bacterial
  supernatant   
Vesicle stability was improved by usage of a longer chain lipid, DSPC (C18). To 
assess sensitivity, systems were tested with bacterial supernatant by overnight 
incubation at 37°C. The fluorescence intensities were used to calculate the SR-
parameter. Results show that 25% TCDA-DS system is less sensitive to S. aureus 
MSSA 476 supernatant, however similar sensitivities are observed on incubation 
with and P. aeruginosa PAO1 supernatants compare to the 25% TCDA-DP system 
(Figure 3.16). Overnight stabilities in HEPES and E. coli DH5a supernatant have 















Figure 0.16: A: Overnight response curves of the 25% TCDA-DP and the 25% 
TCDA-DS systems tested against bacterial supernatants. B: SR-parameters of the 
fluorescence intensities.  







































































































25% TCDA DPPC - supernatant test
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The 25% TCDA-DS vesicles show overall decreased sensitivity compared to the 25% 
TCDA-DP system. This effect in sensitivity may be due to decreased fluidity of the 
bulk DSPC lipids within the membrane, as the DSPC lipids have longer chain lipids 
compared to DPPC, thus the interactions between the chain groups will increase, 
decreasing the fluidity of lipids.  
An abnormality was found during the preparation stage of the 25% TCDA-DS 
system. Following crosslinking of the TCDA vesicles, the solution turned green 
rather than yellow, and gave rise to a green precipitate (Figure 3.17).  In order to 
determine whether the precipitation occurring was due to the use of TCDA in 
longer chain lipids, DSPC vesicles were prepared using varying concentrations of 
TCDA.  
 
Figure 0.17: Crosslinked 25% TCDA-DS vesicles. Upon crosslinking, some 
solutions turned green and a precipitate was observed, whilst other solutions 
showed no difference.- suggesting that incorporation of TCDA into the vesicle 




3.4.8. Studying the effect of changing concentration of TCDA in DSPC 
vesicles   
DSPC based vesicles with TCDA concentrations of 0, 5, 15 and 25% were prepared. 
The 25% TCDA-DS system exhibited formation of green precipitate following 
crosslinking, whereas the other systems showed no precipitate formation. The 
sensitivity to bacterial supernatant and the stability in HEPES was studied by an 
overnight assay (figure 3.18).  
 
Figure 0.18: Overnight stability and sensitivity at 37°C of TCDA-DS vesicles with 
varying concentrations of TCDA. General trend observed: sensitivity increases with 
increasing concentration of TCDA, while stability decreases. 
 
The results of the bacterial supernatant assay suggest that as the concentration of 
TCDA increases, the stability decreases and the sensitivity increases, suggesting 
that TCDA has a de-stabilising effect on vesicles with longer chain bulk lipids, 
rather than a stabilising effect. This can also suggest that instead of creating 
stabilised regions, as in DMPC systems, in systems using longer chain lipids, 
destabilised regions may be forming.  The 15% TCDA shows higher sensitivity and 
lower stability compared to 25% TCDA, suggesting that 25% TCDA was to be a 
more favourable candidate to continue with throughout the project.  
 








































3.5. Summary of Vesicle optimisation  
Table 0.1: Summary of stability of vesicles of various compositions with stability – 
response parameter values, following long-term stability studies. *No increase in 
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More than 70 different types of vesicle formulations were studied within the 
research group, a selection of these vesicles and their SR-parameters are listed in 
Table 3.1. A recent publication in Langmuir details the studies conducted 
comparing the different types of vesicles formulated by other members of the 
group. Three leading vesicle formulations were chosen and their stabilities and 
sensitivities were carefully studied. The leading vesicles were 10% DSPG PD, 15% 
TCDA DS and 2% DOPC DS. The work involving these three vesicles have been 
carried out in conjunction with Serena Marshall, Ph.D. candidate in the Toby 
Jenkins’ research group, University of Bath, UK. This work has recently been 
reported in Langmuir14.  
 
3.5.6. pH stability of  leading vesicles 
Table 0.2: The effect of pH changes on the stability of the three leading vesicles. 
The effect was monitored over a 14 day period. The SR-parameter values were 
calculated following 14 day storage at 37 °C and lysis using Triton X-100. 
Vesicles 
pH stability at 37 °C 
(Stability  Response Parameter, SR) 
 5 6 7 
15% TCDA-DS 3.21 (±0.2) 3.57 (±0.1) 3.70 (±0.2) 
2% DOPC-DS 4.86 (±0.2) 6.41 (±0.4) 2.28 (±0.3) 
10% DSPG-DP 3.84 (±0.8) 4.51 (±0.6) 5.12 (±0.4) 
 
According to the data obtained from the long-term pH stability study, the 15% 
TCDA-DS system showed the most consistent SR-parameter values throughout the 
ranges of pH tests. The 2% DOPC-DS system showed excellent stability at pH 6, 
however a relatively low stability at pH 7. The 10% DSPG-DP vesicle system also 





3.5.7. Sensitivity to whole bacteria and bacterial supernatant  
In these later assays, a different strain of S. aureus to previous studies was used. A 
more clinically relevant TSST-1 (Toxic shock syndrome toxin) producing strain of S. 
aureus, RN4282 was used instead of S. aureus MSSA476 to assess the sensitivities 
of the three leading vesicles. 
 
Figure 0.19: Vesicle response to bacterial supernatant after 100 mins of exposure: 
(1) Triton-X100,(2) S. aureus RN4282, (3)  P. aeruginosa PAO1, (4)  E. coli DH5α, (5) 
HEPES buffer. 
 
The raw fluorescence intensity measurements have been displayed graphically in 
figure 3.19. Overall, all three vesicles systems show stability in E. coli DH5α 
supernatant and HEPES and sensitivity to S. aureus RN4282 and P. aeruginosa 
PAO1 supernatants as well as the control, Triton X-100.  The relatively higher 
response of the 10% DSPG-DP system compared to the other two systems maybe 
due to use of DPPC as the bulk lipids unlike DSPC used by the other two systems. 
Overall weaker interaction of the tail group of the DPPC system can be responsible 
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Table 0.3: SR-parameter values following overnight incubation with pathogenic 
bacteria cells (S. aureus RN4282 and P. aeruginosa PAO1 and relative non-response 
from HEPES buffer, E. coli DH5α, LB broth, TS Broth (TSB) and Triton X-100 was 





































































The results of sensitivity analysis using bacterial supernatant and whole bacteria 
show that the 15%TCDA-DS system was the least sensitive, and that the 10% 
DSPG-DP system was the most sensitive (figure 3.19 and table 3.3). The 2% DOPC-
DS system showed relatively good stability and sensitivity results, however 
reproducibility of vesicle production was low. The relatively lower sensitivity 
observed systems could also be associated as relatively higher stability. As a result, 
although the 15% TCDA system showed the lowest sensitivity, it was used for 





3.6. Conclusion  
 
This study concentrated on formulating vesicles with varying compositions and 
concentrations of stabilising lipids in a constant concentration of 20% cholesterol, 
2% PE with varying concentration of bulk PC (depending on concentration of 
stabilising agent used).  Incorporation of 25% TCDA in vesicles with bulk lipid of 
DMPC was found to show the most desirable stability and sensitivity out of the 
numerous stabilising agents tested.  
Further optimisation of vesicles was achieved by varying the bulk lipid chain 
length; C14, C16 and C18. Replacing the DMPC in the 25% TCDA-DM system with 
the longer chain DPPC (C16) improved the stability of vesicles and subsequent 
analysis using DSPC (C18) showed further stability. The 25% TCDA-DS system was 
proven to have low reproducibility, due to formation of black residue in vesicle 
solutions, which was latter discovered to be TCDA which was not incorporated 
within the vesicle system. Upon analysis of lowing concentrations of TCDA in the 
DSPC system, 15%TCDA-DS vesicles were chosen as the final vesicle candidate for 
further development within the study.  
Validation of the stability and sensitivity of the 15% TCDA-DS system was achieved 
by comparison with two other vesicles systems developed by other members of 
the group. A series of pH and temperature stability assays over a period of 14 days, 
as well as sensitivity assays against whole bacterial culture and bacterial 
supernatant, were carried out and fluorescence intensity values and SR-parameter 
values were compared. The 15% TCDA-DS system were shown to have comparable 
stability and sensitivity features to the other two vesicle systems, thus this system 
was chosen for further development of a wound dressing with pathogenic 
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Chapter Four: Hydrogel and prototype 










This chapter presents the results obtained from the screening process of different 
hydrogels for vesicle immobilisation with respect to their properties to achieve  
optimal vesicle stability and sensitivity. Vesicles were dispersed into simple 
hydrogel formulations; their long-term stabilities at a range of different 
temperatures were assessed, and their sensitivities to whole bacteria as well as 






Due to the amphiphilic nature of lipids and the bilayer of lipid vesicles, the lipid-
based nanocapsules being studied require a moist environment for optimum 
stability. In order to maximise the stability of vesicles, the proposed method is to 
immobilise these vesicles in a hydrogel matrix, easpecially as most commercially 
available wound dressings are hydrogel-based. Furthermore, the proposed use of 
the sensor is for burn wound management along with the development of a 
dressing for burn wound care, which mostly use hydrogel based treatment system.   
 
4.2.1. Polysaccharide gelling agents 
As discussed in Chapter 1, one of the most important factors of a wound dressing is 
its biocompatibility, in order to minimise side effects arising from the composition 
of the dressing. As a result, the use of natural ingredients for development of 
wound care products and pharmaceutical devices is on the increase1.  
In this study, different types of polysaccharides, such as gelatin, guar gum, agar and 
agar derivatives, have been exploited as gelling agents for immobilisation of 
vesicles. Polysaccharide-based gelling agents and gums are widely used by the 
food and cosmetic industries as stabilising and thickening agents and emulsifiers. 
Polysaccharides such as agar and agar derivatives, namely agarose, have been 
utilised in microbiology to provide a solid surface for bacterial growth and as a 
medium for analytical scale electrophoresis for the separation of proteins2.  
4.2.1.1. Gelatin  
Gelatin is an irreversibly hydrolysed form of collagen, often obtained from animals, 
the latter being mostly porcine derived. It is largely used as a gelling agent in the 
food industry, as well as in some pharmaceuticals. Recent developments have 
introduced gelatin as a matrix for tissue engineering3 and as injectable drug 
delivery4. 
Both porcine and synthetic gelatins were studied in this investigation. Gelatin gels 
were formed in HEPES buffer. 
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4.2.1.2. Agar and Agarose 
Agar is a gelling agent obtained from the cell walls of certain species of the 
Rhodophyceae class of seaweed 5. It is a polymer consisting of agarose and 
agaropectin which consists of subunits of galactose6. Agar has a relatively low 
gelling temperature and high melting temperature7. This property is highly 
desirable for scientific use, especially in microbiological applications where high 
incubation temperatures are required (37°C). 
Agarose consists of repeating monomeric units of agarobiose, which is a 
disaccharide of D-galactose and 3,6-anhydro-L-galactopyranose. Agarose is the 
purified form of agar (without agaropectin), and thus exhibits similar properties. 
The low degree of chemical complexity and the broad range of chemical, thermal 
and physical stability of agarose makes it less likely to interact with biomolecules, 
thus, it is often the preferred matrix for use with biological substances such as 
proteins and nucleic acids8.  
4.2.1.3. Polysaccharide gums  
Xanthan and guar gum are both polysaccharides, used extensively in the food 
industry as stabilisers and thickening agents7. Xanthan gum is derived from 
glucose, sucrose or lactose. It  was the first polymer produced by fermentation of 
carbohydrates9. The production of xanthan uses the bacterial stain Xanthomonas 
campestris 10. Guar gum is derived from guar beans. It mainly consists of galactose 




4.2.2. Other hydrogels utilised in this study 
4.2.2.1. Hypromellose  
 
 
Figure 0.1: Chemical structure of Hypromellose 
 
Hydroxypropyl methylcellulose (HPMC), also known as Hypromellose, is a 
synthetic polymer typically used in the pharmaceutical industry to coat active 
ingredients, or in the food industry to use as a vegetarian alternative to gelatin12. 
Hypromellose forms a sticky, viscose and clear gel. The chemical structure of the 
gel is given in figure 4.1.  
4.2.2.2. Polyacrylamide hydrogel foam 
Polyacrylamide hydrogel can be used to produce absorbent foam such as in a 
hydrogel dressing, which could potentially act as a matrix for immobilisation of 
lipid vesicles, as well as act as an absorbent and adhesive hydrogel dressing for 
wound management.  
4.2.2.3. Fmoc protected dipeptides 
The formation of three dimensional hydrogels using dipeptides have been 
investigated for a wide range of applications in the field of biomaterials and 
healthcare development13. These gels have been investigated for use as scaffolds 
for growth of cells for tissue culture, as well as tissue engineering and regeneration 
purposes14.   
Small amphiphilic dipeptide molecules (figure 4.2) have been shown to form 
fibrous structures that entangle and allow the formation of gel through hydrogen 
bonding and π- π stacking between the peptides15. The gelation of these peptides 
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can be induced in a number of ways, including pH change15b, enzyme action16 and 
solvent polarity changes14b.  
 




4.2.3. Properties of gel required for use as a vesicle immobilisation 
matrix 
The primary role of the gel is to act as an immobilisation matrix for the vesicles. 
The gel must not interfere with the activity of vesicles. Therefore, one of the most 
important requirements for the gel matrix is the ability to stabilise the vesicles 
without interfering the lysing mechanism by bacterial supernatant. Upon lysis of 
vesicles, the dye released by the lysis of the vesicle has to be visible; as a result a 
transparent and translucent gel would be beneficial.  
Table 0.1: Gels prepared using HEPES Buffer   
Hydrogel Appearance of gel Physical property of gel 
Agar Colourless, transparent at 
low concentrations of 
gelling agent. However, 
becomes opaque as the 
concentration of gelling 
agent increases. 
Gels set as block at gelling 
agent concentration above 
0.6wt%.  
Agarose Colourless, transparent at 
low concentrations of 
gelling agent. However, 
becomes opaque as the 
concentration of gelling 
agent increases. 
Gels set as block at gelling 
agent concentration above 
0.6wt%.  
Gelatin Slight yellowy coloured gel 
formed. Transparent gel 
formed.  
Gels set as block at high 
gelling agent concentration. 
Can be crosslinked using 
glutamic acid to from gels 
at lower gelling agent 
concentration. 
Hypromellose Clear and transparent gel 
formed.  
Runny with high viscosity 
gel formed.  
Agar/Hypromellose Clear and transparent gel 
formed 
Gel set as block. 
Agarose/Hypromellose Clear and transparent gel 
formed 
Gel set as block 
Xanthan gum Opaque gel formed Runny gel formed  
113 
 
Pectin Opaque gel with slight 
yellowy colour gel formed  
Runny with relatively low 
viscosity gel formed  





Clear and transparent gel 
formed. 
Gel set as block when Uv 
crosslinked. 
Chitosan Clear and transparent gel 
formed.  
Runny gel formed 
 
The table above (table 4.1) shows observed results of the colour, transparency and 
rheological properties of the gels formed. This process allowed for optimised 
choice of gels to be further studied in depth at later stages in the project.  The 
colourlessness and transparency of the gels were two of the main desired 
properties.  As well as the colour, formations of a block gel without the addition of 
further crosslinker were desirable, in order to retain a low degree of chemical 
complexity. The gelling agents that produced gels with potential as vesicle 




4.3. Hydrogel fabrication and initial vesicle stability in gels 
 
4.3.1. Defining stability  
Stability of vesicles in gels can be defined in a similar way to the stability of 
vesicles described in the previous chapter, Chapter 3. Initial stability was 
determined by the colour of the solution on addition of vesicles to the gel solution; 
immediate colour change (yellow to green) indicated unstable vesicles. SR-
parameter values on addition of Triton X-100 and HEPES were calculated. A high 
value was desired on addition of Triton X-100, indicating a high response and a 
low value was required on addition of HEPES (close to 1) indicating stability.  Long 
term temperature stability was measured in a similar manner to vesicles in 
solution. The studies were carried out in 96 well plates, a large increase in 
fluorescence upon lysis with Triton X-100 or bacterial supernatant following 
incubation at 37°C over a period of 14days, indicated stable vesicles.  
 
4.3.2. Stability of vesicles when embedded in hydrogels  
Hydrogels, especially biopolymer gels have been of particular interest recently, 
due to their unique physical, thermal and mechanical properties. Biomimetic 
polymer gels are used in cosmetics, personal care products, and pharmaceutical 
and as encapsulation media of active ingredients. Their ability to hold aqueous 
solutions allows for a constantly hydrated environment, and an ideal environment 
in which to embed lipid vesicles. Various different hydrogels, ranging from simple 
water-soluble polysaccharides to more complex polymer hydrogels have been 
studied in order to obtain the optimum medium for vesicle immobilization and 







4.3.3. Studying the initial stability of vesicles  
Various naturally derived hydrogels were screened with respect to vesicle stability. 
The tabulated results, given in table 4.2, of the initial screening process list a 
number of promising candidates showing good initial vesicle stability.  
Table 0.2: Vesicle stability was assessed by observing for immediate appearance 
of the fluorescence on addition of vesicle solution to gel.  ‘Stable’ in this case 
indicates that fluorescence increase upon addition of vesicle solution to gel was 
not immediate. Unstable indicates that the solution appeared fluorescent 
immediately after addition of vesicle solution to gel. 
Hydrogel Vesicle Type   
TCDA-DM TCDA-DP TCDA-DS 
Agar Unstable Stable Stable 
Agarose Unstable Stable Stable 
Gelatin Unstable Stable Stable 
Hypromellose Stable Stable Stable 
Agar/Hypromellose - Stable Stable 
Agarose/Hypromellose - Stable Stable 
Polyacrylamide 
hydrogel foams 
Unstable Unstable Unstable 
FmocFF Unstable Unstable Unstable 
 
From the results tabulated above, four of the gelling agents listed were taken on 
for further analysis.  Long-term stability analyses were carried out over extended 
periods of time at elevated temperatures. Short-term stability was determined by 




4.4. Vesicle sensitivity in gel matrixes  
The initial stability and sensitivity of vesicles dispersed in gel matrices were 
assessed. Their sensitivity to Triton X- 100 was observed before analysis with 
bacterial supernatant.  Fluorescence measurements were obtained before and 
after addition of lysing agent, and the SR-parameter was calculated. A large 
difference in SR-parameter values was desired between the value obtained on 
addition of Triton X-100 and that of HEPES.  
 
4.4.1. Fmoc FF 
For a 15% TCDA-DS system, vesicles were added to 2mg mL-1 FmocFF gel in a 2:1 
gel to vesicle ratio. Immediate fluorescence increase could be observed on addition 
of the vesicles (figure 4.3).  
 
Figure 0.3: Instability of vesicles when added to 2mg mL-1 FmoFF gel compared to 
HEPES buffer. 
 
The osmolality of the vesicle solution as well as the gel, before formation of a set 
gel, and following formation of a set gel, were tested using an Osmometer. The 
osmometer measures the concentration of solute per kilogram of solvent and an 




Table 0.3: The osmolality and pH of the FmocFF gel as well as the vesicle solution. 
This work was carried out by Charlotte Spencer, MChem student at the University 
of Bath, UK17 
Test solution Osmolality mOsm/kg pH 
FmoFF gel (before gelation) 570 5 
FmocFF (after gelation) 404 - 
Vesicles 212 7.4 
 
In addition to the difference in osmolality, the difference in pH (table 4.3) and large 
fibre formation due to the low pH of the gel could also be the cause of vesicle 
instability18.  
 
4.4.2. Polyacrylamide  
Polyacrylamide gels were fabricated using the materials and formulation supplied 
by First Water Ltd. The gels were formed by the combination of the acrylamide 
monomer, glycerol, water and a photo-polymerising mixture. Vesicle solutions 
were added to the pre-crosslinked gel mixture, and various formulations were 
assembled using different concentrations of water.  Vesicle response was 
measured following addition of Triton X-100. Figure 4.4 shows images of vesicles 
fluorescing upon addition of the pre-gel mixture.  
 
Figure 0.4: images taken under day-light and under UV-lamp at 254nm, indicating 






Gel Type SR- parameter value on addition of Triton 
A 2.05 (± 0.116) 
B 1.47 (± 0.071) 
C 2.04 (± 0.103) 
D 7.39 (± 1.36) 
 
Figure 0.5: Response of vesicles to addition of Triton X-100 and HEPES buffer. A: 
original ingredient of gel B: 1mL of water replaced with vesicle solution from the 
original recipe C: total water content of the original recipe replaced with HEPES 
with additional vesicle solution D: vesicle diluted with HEPES to yield the same 
dilution as in gel mixtures. 
 
Vesicles did not show stability in the polyacrylamide gel, as observed in the data 
and figures given above.  The SR- parameter values on addition of Triton X-100 are 
much lower when added to the mixture of vesicles in gel compared to the control; 
the same dilution of vesicles in HEPES.   






































15% TCDA-DS vesicles were added to a pre-prepared solution of 4% gelatin, in a 
2:1 gel to vesicle solution ratio. The immediate response of vesicles in the gel 
matrix was measured by the addition of Triton X-100 and HEPES as a control.  The 
desired response being an at least 2-fold increase in fluorescence upon addition of 
the lysing agent and as low increase as possible on addition of HEPES.  
The gelatin mixture showed a large SR-parameter of 7.67 (±0.213) on addition of 
Triton and 1.05 (±0.016), a value close to one, on addition of HEPES.  Following on 
from these results, measurements were made on the response of the vesicles in the 








Figure 0.6: The overnight response of vesicles dispersed in gelatin gel to bacterial 
supernatant at 37°C. Vesicles were dispersed into the gel and incubated overnight 
with supernatant of P. aeruginosa PAO1, S. aureus MSSA476 and E. coli DH5α, as 



















































The 2% hypromellose system utilised contained a hypromellose/gel mixture in a 
2:1 ratio. The mixture was tested against Triton X-100. The SR-parameter values 
were 10.1 (±0.398) on addition of Triton X-100 and 0.937 (±0.018) on addition of 









Figure 0.7: Response of vesicles immobilised in hypromellose. Upon incubation 
with supernatant of P. aeruginosa PAO1 and S. aureus MSSA476, a fluorescence 
increase can be observed, along with a slight increase in fluoresce when incubated 



















































4.4.5. Agar and agarose 
The 1% agar and 0.7% agarose systems were used to prepare a 2:1 ratio of gel: 
vesicle mixture.  
As with previous gel systems, the vesicles dispersed in agar and agarose were 
tested with Triton X-100 to obtain SR-parameter values.  The SR-parameter values 
obtained for the agar system were 10.8 (±0.418) on addition of Triton X-100 and 















Figure 0.8: The overnight response of vesicles in (A) agar gel matrix and (B) in 
agarose gel matrix, upon incubation at 37°C with bacterial supernatant; lysis of 
vesicles shown by P. aeruginosa PAO1, S. aureus MSSA476 and the positive control, 
Triton X-100. Vesicles show stability in negative control, HEPES, however slight 
instability is indicated by incubation with E. coli DH5α. Images on the right of each 
graph show the visual response on incubation with Triton X-100 (T), S. aureus 










































































































The plots and the images in figure 4.8 show the response of vesicles in both the 
agar and the agarose systems. Both systems show sensitivity to supernatant of P. 
aeruginosa PAO1 and S. aureus MSSA476. The agarose system yielded a larger 
increase in fluorescence intensity on addition of Triton X-100 and P. aeruginosa 
PAO1 compared to the agar system. The response of both systems was similar to S. 
aureus MSSA476.  A slight increase in fluorescence intensity was detected on 
incubation with supernatant of E. coli DH5α; however the systems were stable in 
HEPES buffer. The properties of agar and agarose are similar; however, due to the 
overall higher responses of the agarose system compared to the agar, the agarose 





4.5. Systematic study of vesicle stability in gels 
Following the short-term stability and sensitivity analysis, the following gels were 
selected for further analysis; gelatin, hypromellose and agarose. The long-term 
stability of vesicles in the gel matrix was studied over a period of 14 days at 37°C. 
This section includes the results of the study involving C981, a carbopol gel system 
that was being examined in parallel by a member of the research group (Serena 
Marshall, University of Bath). The C981 gel was used as a comparative gel system.  
In order to test the gels in a systematic manner, an additional three promising 
vesicle systems were utilised.  
  
4.5.1. Osmolality in relation to vesicle stability  
The C981 gel was used as a comparative model. From the osmotic pressure ratio 
values obtained, see table 4.4 below, the C981 system was predicted to be the least 
stable hydrogel for dispersion of vesicles.  
Table 0.4: The osmolality ratio values were calculated based on the ratio of the 
osmotic pressure (mOsm/kg H2O) of each vesicle type against each solution. A 
value close to 1 is optimal. This table has been modified from the original obtained 
from Marshall et. al. Langmuir 2013.  
 
TCDA-DS DOPC-DS DSPG-DP 
HEPES 1.02 (± 0.004) 1.05 (± 0.002) 1.04 (± 0.010) 
Gelatin 0.960 (± 0.005) 0.984 (± 0.002) 0.977 (± 0.01) 
C981 0.638 (± 0.003) 0.654 (± 0.001) 0.649 (± 0.006) 
HM 0.960 (± 0.004) 0.984 (± 0.002) 0.976 (± 0.009) 
Agarose 0.938 (± 0.004) 0.961 (± 0.002) 0.954(± 0.009) 
LB 1.80 (±3 x 10-5) 1.751 (±4 x 10-6) 1.767 (±0.002) 
TSB 1.446 (±0.001) 1.474 (±0.002) 1.420 (±0.002) 
 
The stability of successfully stabilized vesicles, when dispersed in different 
hydrogel based delivery matrices, was investigated using a long term stability 
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assay, where the vesicles dispersed in the gel matrix are incubated at 37°C over a 
period of 14 days. Upon completion of the 14 day incubation period, vesicles were 
lysed with bacterial supernatant to measure any increase in fluorescence (figure 
4.10).   
 
Figure 0.9: The effect of hydrogel matrices containing the three leading vesicle. 
Vesicles dispersed in each gel formulations were stored at 37 °C for 14 days, 
followed by addition of S. aureus RN4282 supernatant to obtain a value of Ff, or 
HEPES as a negative control. 
From the results obtained (figure 4.9), gelatin and agarose systems showed 
desirable stability and sensitivity for all three vesicles types tested. This is 
indicated by the large difference between ‘Day 14 with HEPES’ and ‘S. aureus 
RN4282 supernatant’. The hypromellose gel showed sensitivity on addition of 
lysing agent, but a relatively poor stability can be observed by the high 
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4.5.2. Detailed vesicle stability in Agarose gel 
The stability of the three vesicle systems in agarose gel was studied over 14 days at 
37 °C in order to better understand whether the leakage of dye was a slow process 
throughout the 14 day period or a sudden burst at a specific point in time. The plot 
in figure 4.10 indicates a slow release in dye throughout the measured time period. 
This suggests that the release of dye is due to a passive leakage from the vesicles 
rather than a release due to lysis of vesicles.  
 
Figure 0.10: Change in fluorescence of three lead vesicle types in agarose gel at 
37 °C over 14 days, and response to lytic supernatant from an overnight culture of 
S. aureus RN 4282 at 14 days. 
  































 TCDA - DS
 DOPC - DS
 DSPG - DP
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4.5.3. Summary of vesicle stability in gel matrixes 
Vesicles were dispersed in solutions of gel prior to the gelation process. The 
stability was primarily judged by observational analysis. Immediate colour 
changes (from yellow to green) on addition of vesicles to the pre-gelation mixture 
indicated instability of vesicles.  On observation of an immediate colour change, a 
low SR-parameter value on addition of lytic agent was seen (close to 1), which was 
not desirable for development as a stability-inducing immobilisation matrix for 
vesicles. For gels which displayed high SR-parameter values on addition of lytic 
agent and a SR-parameter value on addition of HEPES, further gel response studies 
were carried out.  
Following individual response studies on gels, a selection of hydrogels were 
compared to each other along with gels developed by other members of the 
research group. Their long-term stabilities and response to bacterial supernatant 
were studied and compared. The agarose system was identified as an ideal 
candidate for development as a vesicle carrier system.    
In addition to comparing the gel systems, vesicles developed by other members of 
the group were analysed in the different gel matrices. The plot in figure 4.10 
indicates that the DOPC-DS vesicles have the potential to be the ‘ideal’ candidate 
for development of the wound dressing. They show good stability and sensitivity 
throughout most of the gels tested; however, consistent reproducibility vesicle 
production was a hurdle to overcome.  Thus, further studies were carried out using 




4.6. Fmoc FF –Agarose gel multi-layer assembly  
Stabilisation of vesicles in FmocFF gel was unsuccessful. However, the interesting 
property of this gel was used to develop a bacterial ‘logic gate system’ (see section 
4.5.8 for a detailed description). 
As previously discussed, FmocFF can form hydrogel-like structures when 
appropriate gelation techniques are employed. Fibrous structures form and are 
held in place by hydrogen bonding and π- π interactions. Although these structures 
are not held in place by covalent bonding, the effect of addition of protease to 
breakdown the gel was studied. Low concentrations of protease from 
Streptomyces griseus were found to induce breakdown of the FmocFF gel.  
This property of the FmocFF gel was combined with the agarose gel system to 
develop a bacterial logic gate system which responds to the presence of both 
protease and bacterial toxin. The use of lipid vesicles for detection of bacterial 
toxin production has been  reported in previous studies, and the incorporation of 
these vesicles into agarose hydrogels were shown to produce a stable detection 
system for toxin production by pathogenic bacteria19.  
In this investigation, a thin-film bacterial logic gate was engineered using the 
combination of Fmoc-Phe-Phe-OH gels and the agarose vesicle system. 
  
4.6.1. Preparation of FmocFF/agarose gel multi-layer assembly  
A 0.7% agarose gel was prepared in HEPES buffer. The gel was kept at a constant 
temperature of 38°C and vesicles were added in a 2:1 ratio of gel to the vesicle 
solution. 200µL of this mixture was loaded into each well of a 48 well plate and 
allowed to set at 4°C. To protect the vesicles from the FmocFF, 100µL of 0.7% 
agarose gel was added to the top of the agarose gel-containing vesicles. This gel 
was again allowed to set at 4°C. Finally, 2mg mL-1 FmocFF gel was prepared and 
allowed to gellate on the surface of the two agarose layers, to obtain the final 
FmocFF/agarose gel s multi-layer assembly. Figure 4.11 shows a cartoon 









Figure 0.11: Diagram of gel multi-layer assembly 
 
4.6.2. Testing the response of gels  
Protease was added to the multi-layer assembly of gels and the agarose gel 
systems in 24 well plates. The plate was incubated at 37°C for 1hr to allow the 
breakdown of FmocFF gels. Following on from this, 100µL of bacterial supernatant 
and the corresponding controls were loaded on top of the gels and incubated 
overnight. Well scans were taken (using a BMG Labtech Fluostar Omega microplate 
reader, with excitation and emission filters of 485 and 520 nm, respectively) to 
measure lysis of vesicles in the agarose/vesicle layer: prior to the addition of 
protease; following 2hr incubation; and following overnight incubation at 37°C.  
 
4.6.3. Protease assay 
An agar petri dish compromising of 10% milk in brain heart infusion agar was 
prepared by mixing the milk solution to the agar, post autoclaving. Six 1cm 
diameter perforations were made on the agar plate and the holes were filled with 
50µL of bacterial supernatant and corresponding control solutions. The plate was 












supernatant   
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4.6.4. Breakdown of FmocFF gel on addition of protease 
Protease-induced breakdown of FmocFF gel was examined by means of 
comparative studies of protease added to a pre-formed gel and water added to an 
identical gel. The vials containing the FmocFF gel and each of the test solutions 
were inverted. Figure 4.12 shows the image of the vials illustrating intact gels 
when water was added, and collapsed gels when exposed to protease. This 
suggests that protease can include breakdown of FmocFF gels.    
 
Figure 0.12:  Image showing breakdown of FmocFF gel on addition of Protease 
using water as a control. 
 
4.6.5. Stability and sensitivity of the FmocFF multi-layer assembly 
system  
The gel systems were prepared in wells of 24 well plates. 100µL of Protease from 
Streptomyces griseus was carefully pipetted on top of the FmocFF gel, water was 
pipetted as a control to an identical plate, both plates were incubated for at least 
an hour to allow initial breakdown of the peptide gel layer. Following the initial 
incubation stage, 100µL of bacterial supernatant and the corresponding controls 




4.6.6. Response of vesicles in agarose with the additional pure-
agarose layer to bacterial supernatant  
The initial response of vesicles to bacterial supernatant in the presence and 
absence of protease was confirmed. The gel multi-layer assembly was prepared, 
without the FmocFF layer and protease was loaded into each well, and incubated 
for at least an hour before addition of bacterial supernatant. The fluorescence 
intensity of vesicles incorporated in the bottom agarose layer was measured after 







Figure 0.13: Stability response Parameter, SR, calculated and graphed for time 
points; T=2 h and T=18 h, following initial incubation of agarose/vesicle layer with 
the additional pure agarose layer (without the FmocFF gel layer) with water (a) 
and protease (b) for 1 h followed by 18 h incubation with bacterial supernatant at 
37°C. 
 
Vesicles were responsive to supernatant of P. aeruginosa PAO1 following 2 h 
incubation in the absence and presence of protease. However, vesicles showed 
response to S. aureus MSSA 476 after 18 h incubation in the presence of protease 
and a response at 2h in the absence of protease. The data indicates a slight 
destabilisation on addition of supernatant of E. coli DH5α and water in the 
presence of protease.  In the presence of protease, a delay in the response of 
vesicles to S. aureus MSSA 476 can be observed, however following 18h 







































4.6.7. Response of the gel multi-layer assembly to bacterial  
supernatant in the presence of protease   
The complete gel multi-layer assembly complex with the additional FmocFF layer 
on top of the pure agarose layer was incubated with protease, followed by 
incubation with bacterial supernatant. The fluorescence of vesicles in the bottom 
agarose layer was measured after 2h incubation and on completion of the 18h 
incubation period at 37°C. The FmocFF gel layer was broken-down by the initial 
incubation with protease. As a result, the subsequently added bacterial 
supernatant was able to diffuse into the agarose gel layer, and to lyse vesicles 
immobilised within the bottom agarose layer. The large SR-parameter upon 
addition of S. aureus MSSA476 and P. aeruginosa PAO1 indicates lysis of vesicles 



















Figure 0.14: Stability response Parameter, SR, calculated and graphed at T=2h and T=18h 
following initial incubation of complete gel multi-layer assembly system with protease 
for 1 h, followed by 18h incubation with bacterial supernatant at 37°C. Statistical 
analysis were carried out by a Student’s t-test, * P- value > 0.05, **P value  < 0.05 
From the results (figure 4.14), as well as the previous results obtained on the 
breakdown of FmocFF gels following incubation with protease and stability of gels 







protease, the FmocFF gels should be stable and thus the vesicles dispersed in the 
bottom layer of agarose should not lyse, regardless of the additional incubation 
with toxin-producing bacterial supernatant.  
The above assay was repeated with addition of water instead of the initial addition 
of protease. As expected, without the addition of protease, the FmocFF gel layer 
inhibits the diffusion of toxins of S. aureus MSSA467, and stable vesicles can be 
observed by the low SR-parameter value obtained (figure 4.15). However, on 
incubation with P. aeruginosa PAO1, lysis of vesicles was observed following 2 h 
incubation. These results suggest the presence of protease in the P. aeruginosa 
PAO1 supernatant in sufficient enough concentrations to breakdown the FmocFF 










Figure 0.15:  Stability response Parameter, SR, calculated and plotted at T=2h and T=18 
h following initial incubation of the complete gel multi-layer assembly system with water 
for 1h, followed by 18h incubation with bacterial supernatant at 37°C. Statistical analysis 


























The results depicted in figure 4.15, indicate that P. aeruginosa PAO1 produces 
sufficiently high concentrations to cause breakdown of the FmocFF gel layer. This 
was tested using a simple proteolytic plate assay (figure 4.16).  
 
Figure 0.16: 10% milk BHI agar plate incubated with supernatant of P. aeruginosa 
PAO1, S. aureus MSSA476 and E. coli DH5α and protease as a positive control and 
broth solutions as negative controls, overnight at 37°C. 
 
The formation of the halo-ring, displayed in figure 4.16, around the well which 
contained supernatant of P. aeruginosa PAO1 is also seen around the well which 
initially contained the control solution, protease. The halo-ring is absent around 
the wells which contained supernatant of S. aureus MSSA476 and E. coli DH5α as 
well as the two broth solutions used a controls.  This suggests that the P. 
aeruginosa PAO1 produces protease in high enough concentrations to breakdown 
the proteins.  
 
4.6.8. Microbial Logic gate 
The gel multi-layer assembly system developed in this section is comprised of two 
responsive layers. The top layer consists of the protease responsive FmocFF gel 
and the bottom layer consists of vesicles dispersed in agarose gel, responsive to 
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bacterial toxins. From the results presented in this section (Section 4.5), the multi-
layer assembly system can be described as a logic gate AND system. Table 4.5 
demonstrates this in a tabulated form.   
Table 0.5: Representation of logic gate  
Protease Toxin Result 
1 1 1 
1 0 0 
0 1 0 
0 0 0 
 
A logic gate describes a device that performs a logical operation by one or more 
inputs, which work in a logical way to produce a single logical output. A Boolean 
function is used by the device. In order for a logic gate system to be described as an 
AND system, the binary digits representing all the inputs have to display 1 in order 
to produce an output of 1. If one or more of the outputs display a 0, then the output 
binary digit will also be 0. 
The gel system described in this section required the presence of protease and 
lytic toxin for a fluorescing gel. Consequently, if the protease and lytic toxin are 
described as the inputs and the resulting fluoresce of gel as the output, this system 




In this chapter, the stability of vesicles was tested in a range of different hydrogels. 
A few of the leading systems were compared to systems developed by other 
members of the group. Through systematic analysis, the 15% TCDA- DS vesicles in 
agarose gel were revealed to show desirable stability and response of vesicles 
incorporated in the gel matrix.  
Furthermore, a gel-multilayer system was developed, where an additional 
protease responsive FmocFF gel layer was added to the 15% TCDA-DS in agarose 
system. This allowed for further enhanced sensitivity to the already developed 
lytic toxin sensitive lipid based system, sensing for the presence high enough 
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5.1. Introduction  
 
The goal of the development carried out through this study is to produce a 
definitive dressing that indicates bacterial colonisation of the wound site. Most 
importantly, the dressing should not interfere with the wound healing process. In 
order to achieve this, the production of the dressing has to involve biocompatible 
material, with minimal cytotoxic effects and minimal disruption to cell 
differentiation.  
In recent years, in vitro assays are being favoured over animal tests due to the cost, 
availability and rapid results of assays, as well as the ability to avoid negative 
publicity in the case of public discontent with animal testing. The development of 
hepatocyte cell lines with metabolic capabilities will allow testing of drug 
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metabolism and toxicity. Keratinocyte cell lines have been developed for assays 
involving toxicity testing of new topical drugs and treatments as well as 
conducting cell proliferation and growth assays.1  
5.1.1. Eukaryotic Cells 
Eukaryotic cells are complex multicellular cells which make up plants and humans. 
Cell structures are more complex compared to prokaryotic cells (figure 5.1). 
Eukaryotic cells consist of a cell membrane, which contains a cytoplasm in which 
the biochemical reactions of the cell occur and contains the nucleus, the 









Table 5.1: Image showing the structure of a human Eukaryotic cell1. 
 
5.1.2. Use of Keratinocyte cell lines in in vitro assays  
HaCaTs are immortalised keratinocytes obtained from the human skin. This cell 
line has been used by the research denomination for in vitro testing of various 
drugs and treatment methods developed involving the skin2. 
Although HaCaT cells have been immortalised, they retain the differentiation and 
morphologies of keratinocytes. They can be grown in normal growth medium3, in 
contrast to the primary keratinocytes  where cells obtained from a fresh skin 
sample require supplementary growth factors to survive in vitro. Furthermore, 
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they die quickly, making long-term studies hard to achieve4. As a result, HaCaTs 
are considered to have attractive aspects for use in an in vitro model for 
cytotoxicity assays. Moreover, in vivo, keratinocyte cell lines are the cells which are 
exposed to the topical products5.  
The compatibility of hydrogel dressings have been tested using HaCaT cell lines. 
HaCaT cell lines were used to test for the presence of cytotoxic components6. 
Previous studies used pre-incubated HaCaT cells to assess cytotoxicity by further 
incubation in media with suspended hydrogel components/extracts6,7.  
5.1.3. Use of Fibroblasts cell lines in in vitro assays 
As well as keratinocyte cell lines, fibroblast cells lines are often used to perform 
cytotoxicity analysis of novel nanoparticles and dressing material8, 6. EA.hy926 is 
one of the most utilised human vascular endothelial cell line. The cell line was 
generated in 19839, and has been in use ever since for in vivo analysis, including 
cytotoxicity analysis10.  
 
5.1.4. Cell viability assessment  
Cell viability was examined using assessment of mitochondrial activity, which 
correlates well with cell proliferation. The assays used for this are usually based on 
the use of a dye which reacts with a component of the mitochondria which can be 
detected due to a change in the colour of the dye. An example of a dye which reacts 
in this way is tetrazolium salt 3-[4,5-dimethylthiazolyl-2]-2,5-diphenyl tetrazolium 
bromide (MTT)6. An Alamar Blue  assay involves the change of the colour of a dye, 
the assay comprises of resazurin which is reduced to resorufin by NADPH in the 
electron transport chain between the final reduction of oxygen and cytochrome 




5.2. Methods and materials used for cytotoxicity assays  
 
The preliminary studies involved testing of cytotoxic effects of vesicles with 
respect to eukaryotic cells. Studies were carried out using two different cell lines; 
HaCaT, which are skin keratinocytes and Eahy926, which are blood vessel 
fibroblasts. Cell viability was measured using the Resazurin reagent obtained from 
Sigma Aldrich. 
 
5.2.1. HaCaT and EA.hy926 Cell culture for cytotoxicity  
Detailed descriptions of the techniques used for preparation of 70% confluent cells 
in T75-cm2 flasks can be found in Chapter 2 of this document. Preparation of 
eukaryotic cells for analysis of cytotoxicity of vesicles and gels in solution were 
carried out in 24 well plates. Hepatocytometer was used to obtain cell density of 
1x105 cells mL-1, 1mL was used to seed cells into each well. The cells were allowed 
to proliferate overnight under tissue culture conditions of 37°C and 5% CO2. 
Following overnight incubation, the media was removed from the wells, washed 
with 1mL PBS (twice) and wells were replenished with fresh media containing 
testing solution.  The cells were then further incubated for 24, 48 and 72 h under 
tissue culture conditions.      
5.2.2. HaCaT and EA.hy926 Cell culture for supernatant assays 
Cell seeding density of 1x104 cell mL -1 was used to seed 100µL onto each well of 
tissue culture 96 well plates (final cell density of 1x103 cells mL-1 in each well) and 
allowed to proliferate overnight. Following overnight incubation of cells, the media 
was removed, cells were washed in PBS and media was replenished with media 
containing vesicle solution. Following this procedure pre-diluted bacterial 
supernatant and the appropriate control solutions were added, before further 
incubation of 2 h under tissue culture conditions. After the 2 h incubation period, 
media was removed and transferred to a fresh 96 well plate for fluorescence 
measurements of vesicles. 10% resazurin in media was added to the remaining 
cells in the tissue culture plate and further incubated for 2h. The fluorescence of 
resazurin was then measured to assess cell viability.  
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5.2.3. Viability measurement  
The viability of cells following exposure to vesicles was determined using the 
resazurin dye assay. Following exposure to vesicles, cells were incubated with 10% 
resazurin at 37°C for 2h. The fluorescence was measured using a BMG Lab Tech 
microplate reader with excitation and emission filters of 530nm and 580nm, 







































































































































































Ea.hy 926 Cell Calibration curve (96 well plate)
5.3. Results and discussion of cytotoxicity results 
 
 The cytotoxic effects of vesicles were tested on Eukaryotic cells. Keratinocyte, 
HaCaT cells as well as fibroblast, EA.hy926 cells were used for this analysis. As well 
as the cytotoxic effects of vesicles, the stability of vesicles in a eukaryotic 
environment was also studied by measuring their fluorescence increase upon 
addition of a lysing agent, following 24h incubation with eukaryotic cells.  
 
5.3.1. Initial the calibration curve  
The initial construction of calibration curves for each cell line in the different well 
plates was required for calculation of the number of cells per mL in a well plate for 










Figure 5.1: Calibration curves for HaCaT and EA.hy926 cell lines 
 
The calibration curves were used to determine a rough estimate of the initial cell 

























































1x104 cells mL-1 was used for assays carried out in 96 well plates, and 2x105 cells 
mL-1 was used for assays carried out in 24well plates.  
 
5.3.2. Initial cytotoxicity analysis  
An initial cytotoxicity assay was carried out over a period of 24 h for both types of 
cell lines. Cells were seeded onto 24 well plates and allowed to grow overnight, to 
obtain 70% confluent monolayer of cells on the surface of the tissue culture plate. 
Following on from this, the media was removed and replenished with fresh media 
containing each testing solutions; vesicles, lysed vesicles, Triton X-100 and HEPES. 
The lysed vesicle solution was prepared by a heat treatment process rather than 
the conventional method of addition of triton, as triton is also a solution used to 
obtain dead cells. 











































Figure 5.2: Results of cytotoxicity assay, showing non-cytotoxic effects of vesicles as well 
as lysed vesicles compared to the HEPES and pure media control to both types of cell lines. 
 
Cell death can be observed by the low fluorescence value of resazurin. And cell 
viability was identified by fluorescence values of resazurin close to the values 
obtained from incubation in ordinary cell growth media. Both vesicles and lysed 
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vesicles were shown to have no significant initial cytotoxic effects when incubated 
over a period of 24h.  
 
5.3.3. Stability of vesicles in the presence of eukaryotic cells  
In addition to studying the cytotoxic effects of vesicles to eukaryotic cells, the 
stability of vesicles in the presence of eukaryotic cells was also studied. Following 
24h incubation of cells with media containing each testing solution, i.e. vesicles and 
lysed vesicles, this media was removed and transferred to a 96 well plate. And the 















Figure 5.3: Stability of vesicles on incubation with HaCaT (top plot) and EA.hy926 
cells (bottom plot). Following 24 h exposure to eukaryotic cells, stability was 
assessed by fluorescence intensity measurements on addition of Trion X-100 and 
HEPES.  












































Stability of vesicles to HaCaT cells over 24 hr 











































Vesicle stability following 24hr incubation with EA.hy926 cells 
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5.3.4. Cytotoxicity of vesicles tested in well plates over 24, 48 and 72h 
The 24h cytotoxicity assay presented promising results showing no significant 
cytotoxicity of vesicles to cells. The same assay was carried out for a longer 
incubation period; 24, 48 and 72h with results displayed by figure 5.4.  
 
 
Figure 5.4: Shows the viability of HaCat cells when exposed to media containing 
vesicles over a period of 24, 48 and 72h. Resazurin assay was used to study the 
viability of cells. 
 
The experimental resazurin fluorescence values were converted to cell density mL-
1. The graph plotted from these results indicates minimal cytotoxicity of vesicles as 
well as lysed vesicles compared to when cells were incubated with Triton X-100, 
where complete cell death can be observed.  
  








































5.3.5. Confocal images of cell incubated in media containing vesicles 
Cell growth in tissue culture medium was compared to cell growth in tissue culture 
medium containing vesicle solution by observation using confocal imaging.  
 
Figure 5.5: Confocal images of HaCat cells (A) vesicles incubated with HaCat cells 
(B) over a period of 24h. Stained with neutral red solution at X40 magnification. 
 
Confocal images (figure 5.5) show similar cell growth patterns when cells were 
incubated in media containing vesicles and in media without vesicles. The image 
indicates the possible presence of both lysed and intact vesicles inside and outside 
the cell membrane. Thus there is the possibility that the cells uptake the vesicles.  
The uptake of vesicle by cells can be anticipated, as vesicles are only 100nm in size, 
and the compositions are similar to the compositions of the cell membrane. 
Furthermore, lysosome formation is a process which occurs within a cell as a 
mechanism of uptake of active ingredients.   
 
5.3.6. Cellular response to vesicles in conjunction with bacterial  
supernatant  
Vesicles were incubated with HaCaT cells along with bacterial supernatant at 
different concentrations. AGR positive (RN6390B) and negative (RN6911) strains 
were used to study the effect of eukaryotic cells on lysis of vesicles. As previously 
discussed, S. aureus strain AGR+ produces the toxins which lyse vesicles and lyse 
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eukaryotic cells, and S. aureus strain AGR- does not produce this toxin therefore 
should not lyse vesicles, neither should the eukaryotic cells.  The AGR positive and 
negative systems show direct relevance to the system being developed since, as 
previously mentioned in Section 1.2.5.3. of Chapter 1, δ-toxin toxin is the major 
toxin responsible for lysis of membrane, and the production of this toxin is directly 
governed by the AGR system.  




Figure 5.6: Showing response of vesicles to bacterial supernatant in a eukaryotic 
cell environment.  
 
The plots above show that in order to achieve 80% cell death, a 50% supernatant 
dilution of AGR+ S. aureus RN6390B is required, whereas to achieve 80% vesicle 
lysis, a 30% supernatant dilution of AGR+ S. aureus RN6390B is required. In terms 
of the median lethal dose (LC50) of bacterial supernatant on cells, the value is at 20% 
supernatant dilution, whereas the corresponding value for vesicles (the median 
lethal dose of vesicles, V50) is approximately 5% supernatant dilution. This is an 
indication that vesicles may be acting as an ‘early warning system’, providing 
evidence for the presence of pathogenic bacteria before cell damage occurs. 
Furthermore, the stability of vesicles as well as the lack of response by cells to 
AGR- S. aureus RN6911 suggests that vesicles will not lyse in the presence of non-
toxin-producing bacteria.  
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As previously stated, the major toxin involved in lysis of cells and thus lysis of 
vesicles is δ-toxin. With the assumption that δ-toxin  is the leading toxin involved 
in lysis of vesicles and cells, in order to determine the concentration of  lytic 
proteins in the supernatant dilutions used, serial dilutions of δ-toxin were used to 
lyse vesicles and the fluorescence intensities were measured. According to the 
results in figure 5.7, assuming that V100 occurs with the addition of triton, V50 
occurs at δ-toxin concentration between 2 and 2.5µM. As a result, one can estimate 
that approximately 5% supernatant dilution contains approximately 2µM 
concentration of δ-toxin. Thus approximately 2 µM concentration of δ-toxin is 
required for V50 and approximately 8 µM concentration of δ-toxin is required for 






































































Figure 5.7: Vesicle lysis using serial dilution of pure δ-toxin 
 
Furthermore, this study has shown that the activity of vesicles was not affected by 
presence of eukaryotic cells; vesicles were both stable to non-toxin-producing 
bacterial supernatant and responsive to toxin-producing bacterial supernatant in 
the presence of eukaryotic cells (HaCaT).  
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Gel cytotoxicity - Ea.hy926
5.3.7. Cytotoxicity of gels in suspension  
In addition to testing the cytotoxicity of vesicles, the cytotoxicity of the hydrogels 
intended to be utilised in prototype development were tested.  Pure media was 
used as a positive control of stability and Triton X-100 as a negative control 
indicating cell death. The assay was carried out in a 24 well plate with initial 
seeding density of 2x105 cells mL-1. The cells were allowed to proliferate and grow 
to obtain 70% confluent cells in each well. The wells were washed in PBS and 
media containing test material were added. The cells were further incubated for 
24h before conducting the cell viability assay using 10% resazurin solution in 
media.  
 
Figure 5.8: Response of eukaryotic cells to hydrogels dissolved in cell growth 
media over a period of 24h at 37°C and 5% CO2. The viability of vesicles was 
measured using the resazurin assay. 
 
Figure 5.8 displays the results obtained from the cytotoxicity assays indicate that 
the media containing hydrogels had minimal effect on the growth of established 
cells, compared to the cells incubated with Triton X-100, were complete cell death 













































Gel cytotoxicity - HaCaT Cells 
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5.4. Conclusions  
 
Eukaryotic cells were used to assess the cytotoxicity of vesicles as well as any 
other materials planned for use in development of the prototype dressing.  From 
the analysis carried out in this section, it can be proposed that vesicle lysis will 
occur before the toxins produced by the bacteria lyse the eukaryotic cells as the V50 
of was lower than the LC50. Vesicles lysis following incubation with serial dilutions 
of pure δ-toxin allowed approximation of the concentration of δ-toxin required to 
obtain V50 and LC50; respective values of 2µM and 8µM were obtained. 
Furthermore, no significant cytotoxic effects of hydrogels, intended to be utilised in 
prototype development, were found over a 24h period.  
In conclusion, the vesicles and the gels being developed did not show significant 
evidence of cytotoxicity; hence, these components were used for further 
development.   However, the in vitro assays carried out within this chapter utilized 
immortalised cell lines, which have been mutated to improve proliferation and 
prolonged growth.  In order to obtain more representative results, the assays 
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6.1. Introduction to prototype development  
 
Commercially available hydrogel wound dressings are thin sheets of hydrogel on a 
semi-permeable plastic backing. Thus thin sheets of the gel with immobilised 
vesicles were fabricated and tested; these were referred to as gel-block systems. 
Throughout the study, limitations involving the gel-block system were identified, 
and gels were used to coat single sheets of fabric to overcome the limitations. As 
well as simple prototypes involving vesicles in a hydrogel system, an additional 
collagen coating allowed the formation of a prototype dressing with the capability 
of enhancing wound healing.  
6.1.1. Wound Healing Process  
Skin injury causes disruption to the tissue as well as to the surrounding blood 
vessels. An initial provisional extracellular matrix provides an environment for cell 
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migration. Macrophages and fibroblasts are activated by the platelets, which 
remove any debris and begin the process of wound closure. The wound healing 
process has been summarised by Schultz1 into five stages which involve complex 
cellular and biochemical processes. The five stages are described as haemostasis, 
inflammation, migration, proliferation and maturation (remodelling) phases 
(figure 6.1).  
 
 
Figure 6.1: Diagram showing the different stages of wound healing process 
following an injury 
 
6.1.1.1. Coagulation and inflammation  
The preliminary response of the body upon occurrence of an injury is bleeding; 
this process removes bacteria and antigens from the wound site. This bleeding 
process causes the activation of haemostasis, in which the blood clots and platelets 
are engaged to form a temporary seal2. Simultaneous to the process of haemostasis, 
the inflammation phase occurs. This phase involves vascular as well as cellular 
responses. Vasodilation occurs due to the release of exudate, containing histamine 
and serotonin, allowing macrophages to enter the wound site to remove necrotic 
tissue. Neutrophils are also activated and begin to clean up the wound site of all 
foreign particles as well as any bacteria.  
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6.1.1.2. Migration and Proliferation 
The migration phase follows the inflammation stages. This process involves the 
migration of epithelial cells and fibroblasts to the wound site.  Along with the 
migration phase, the proliferation phase also involves the movement of cells. 
Extracellular matrix, such as collagen, is produced by fibroblasts allowing 
migration and cellular adhesion of keratinocytes3, capillaries and lymphatic vessels. 
Collagen is an essential component giving the skin its strength and form4. 
6.1.1.3. Maturation and remodelling  
The final stage of the wound healing process is the maturation and remodelling 
phase, involving the re-organisation of extracellular matrix, strengthening the 
epithelium and forming the connective tissue between cells. This is the stage which 
governs the final scar formation4.  
6.1.1.4. Abnormal wound healing 
Chronic conditions such as diabetic foot ulcers have prolonged inflammation, 
impaired neovascularisation, a decreased synthesis of collagen, an increased level 
of protease, and a defective macrophage function, thus are prone to infection. 
Infection can delay the wound healing process. 
 
6.1.2. Wound management  
When managing skin injuries such as a burn, the aim is to achieve wound closure 
within the shortest period of time. The process of wound management involves 
several steps, including wound cleansing and debridement, followed by application 
of a dressing to keep the wound site moist and infection-proof, and promote 
healing. The wound healing process follows various complex steps, as described in 
section 6.1.1; disruption of any of these steps can result to delayed wound healing, 
scar formation and increase chances of infection.  
 
6.1.3. Summary  
The wound healing process involves various different stages, proteins and cell 
types. One of the most important factors in wound management is to minimize 
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disturbance of the self-healing process. Infection control is a major concern in 
wound management; faster wound closure and creating a barrier to prevent 
bacteria from entering the wound site can minimize the possibility of infections.  
Therefore design of a dressing that can protect the wound from external bacteria 
from entering as well as encourage faster wound closure, using hydrogels to retain 
a moist environment and biological material to provide an extracellular matrix for 
cell growth, would be advantageous.  
From the results obtained in the previous section, the 15% TCDA-DS vesicles were 
chosen for further analysis. In this section, 15% TCDA-DS vesicles were 
incorporated into various gels selected from previous studies. Two types of 
prototype systems were examined; gel-block system where vesicles are dispersed 
in the matrix and a gel-coated fabric system where vesicles dispersed in a gel 




6.2. Gel-block type wound dressing  
 
Current commercially available wound dressings such as Mepitel™ consist of a 
layer of hydrogel on a skin-coloured backing. As discussed in Chapter 3 and 4, the 
15%TCDA –DS system showed the desired stability and sensitivity in various 
different conditions and gel matrixes. As a result, thin gel sheets with immobilised 
vesicles were fabricated and their stability and sensitivity was investigated. 
 
 
Figure 6.2: A: Cartoon representation of the structure of the gel-block type wound 
dressing. B: Photographic image of the gel-block system under day light (left) and 
under UV-light (right) 
 
The block-gel forming agents gelatin, agar and agarose were used in this study, and 
sensitivity assays were carried out using the standard strains of bacteria,  S. aureus 








6.2.1. Stability and sensitivity of Gelatin based gel-block type wound 
dressing 
The overnight stability and sensitivity of gelatin based gel-block type wound 
dressing was tested at 37°C. The stability of the gel-block system was tested by 
incubation in HEPES and non-toxin producing bacterial supernatant, E. coli DH5α. 
The sensitivity of the gel-block system was tested by incubation in the supernatant 
of S. aureus MSSA476 and P. aeruginosa PAO1. The photographic image shows the 






Figure 6.3: Overnight stability and sensitivity study of vesicles in gel-block system. 
The fluorescence of a 12 well plate was measure in an overnight study. Plot shows 
responsive vesicles in toxin producing bacterial supernatant, and stable vesicles in 
HEPES and E. coli DH5α. 
 
The gelatin gel-block system displayed a visual colour change following incubation 
of the system in bacterial supernatant overnight at 37°C. Furthermore, this change 
was not observed for the negative controls nor for the wells incubated with E. coli 
DH5α (figures 6.3). These visual results were further confirmed by the overnight 
fluorescence measurements, which presented with an immediate response of 
vesicles to supernatant of P. aeruginosa PAO1 as well as the positive control 
(Triton X-100) and a gradual increase in fluorescence was shown by treatment 
with S. aureus MSSA 476.  The delay response of vesicles in gel to MSSA 476 
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compared to PAO1 may be due the relatively slow diffusion of δ-toxin compared to 
rhanmolipid, which is the lysing agent responsible for lysis of membranes found in 
supernatant of PAO1.  
 
6.2.2. Stability and sensitivity of Agar and Agarose based gel-block type 








Figure 6.4: Average well scans of before addition of supernatant and after addition 
of supernatant and incubation at 37°C on agar gel-block systems.  
 
The agar gel-block (figure 6.4) and the agarose gel- block (figure 6.5) type systems 
show responses to toxin producing bacterial supernatant. However, better stability 
was observed for the agarose system compared to the agar. Lower initial 
fluorescence (T=0) was observed for the agarose system in comparison to the agar. 
Furthermore, the high fluorescence intensity at T=18 of wells containing DH5α 
supernatant and HEPES for the agar system, can be evidence of leakage or 























































Figure 6.5: Average well scans of before addition of supernatant and after addition of 
supernatant and incubation at 37°C on agar gel-block systems. 
 
6.2.3. Confocal imaging  
A thin layer of the agarose gel-block system was prepared on a glass slide for 
image studies using confocal microscopy. The concentration of vesicles used was 
reduced to minimise background fluorescence during imaging, to approximately 
1x108 particles mL-1 instead of approximately 1x1012 particles mL-1.  
 
Figure 6.6: Cross section image of Z-stack of a thin layer of agarose gel-block 
system with vesicles of an approximate concentration of 1x108 particles mL-1. 
 
The confocal cross section image of the gel shows a uniform distribution of single 
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With the success of imaging single vesicles in the agarose gel-block system, the 
lysis and stability of vesicles on addition of toxin-producing bacterial supernatant 
and non-toxin-producing bacterial supernatants were prepared for imaging The 
AGR+ S. aureus strain, RN6390B and the AGR- S. aureus strain RN6911 were used. 
As well as the AGR +/- strains, a methicillin-resistant Staphylococcus aureus (MRSA) 
strain USA300 (Lac) was also used to image the effect on vesicles.   
 
Figure 6.7:  Thin layer of 15% TCDA-DS vesicles immobilised in agarose gel matrix 
confocal images of TCDA-DS vesicles immobilised in agarose gel on glass slide was 
imaged using confocal. Top row: effect of AGR- stain of S. aureus RN6911 
supernatant on vesicles in gel matrix captured over time, showing no increase in 
background fluorescence over a 00, 60 and 120s time period. Middle row: effect of 
AGR+ stain of S. aureus RN6390B supernatant on vesicles in gel matrix over time, 
showing increase in background fluorescence within the first 60s. Bottom row: 
effect of S. aureus USA300 supernatant on vesicles in gel matrix over time, showing 




The confocal microscopy images (figure 6.7) show that vesicles in the agarose gel 
system do not respond to supernatant of AGR- strain of S. aureus RN6911 within 
the time frame of 120s. Whereas an immediate increase in background 
fluorescence can be observed (at 60s), on addition of supernatant of AGR+ stain of 
S. aureus RN6390B.  Furthermore, on addition of supernatant of lac USA300, an 
even larger increase in background fluoresce can be observed at 60s.  
6.2.4. Limitations of the gel-block systems 
The gel-block system has shown promising results in terms of sensitivity and 
stability of vesicles though overnight studies, measuring the change in 
fluorescence intensity. However, some limitations of the gel-block system have 
been identified.  
6.2.4.1. Thickness of gel 
The gel-block prototype presented so far have been fabricated by setting 500µL of 
gel/vesicle mixture into each well of a 12 well plate. Following complete gel 
formation, the thickness of the gel was measured to approximately 3mm. For the 
purpose of stability and sensitivity analysis, 500µL of control solution and 
bacterial supernatants were pipetted on top of the gel-blocks. Following overnight 
incubations at 37°C, only the vesicles on the top surface of the gel had lysed (figure 
6.8).  This was thought to be due to two main reasons; concentration of vesicle 
lysing agent in the bacterial supernatants and/or the slow diffusion rate of the 
lysing agents.  
 
Figure 6.8. The effect of the thickness of gels on the diffusion of toxins from 
supernatant for lysis of vesicles. The thickness of the gel was measured to be 




In order to overcome this barrier involving the thickness of the gel, a thinner gel 
block system was produced. However, the thinner gel-block systems were shown 
to be very fragile and more difficult to manage. Furthermore, dehydration of the 
gel matrix, causing vesicle lysis, was another major hurdle to overcome.  




Figure 6.9: Image showing the effect of gel dehydration on stability of vesicles. 
Top three images were taken under day light and the bottom three images were 
taken under UV-light. 
In addition to the thickness of the gel, dehydration of the gel-block system is a 
major issue for storage purposes. The image above shows agarose gel-block 
system stored in a sealed container over a period of 21 days. Images were taken on 
days 1, 10 and 21. Despite the low temperature and the sealed container, the gel-
block system appears to have dried out by day 10, and the change in the colour of 
the system is visible under UV-light.  
 
6.2.5. Summary of the gel-block system 
A number of different gel block systems were developed using three gels that 
showed formation of block-gels from previous studies reported in Chapter 4. Out 
of the three gels, the system using agarose showed the most stable and sensitive 
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to Lac supernatant within 60 seconds of addition of supernatant and unresponsive 
to AGR- strain over a period of 120 seconds, when a very thin layer of gel was used. 
However, the block system exhibited slow diffusion of lysing agents when a thick 




6.3. Gel coated fabric wound dressing 
 
Figure 6.10: Diagram of the gel coated fabric system 
 
The gel coated system was prepared by dip-coating a piece of fabric in the 
gel/vesicle mixture (2:1 ratio). The coated pieces of fabric were allowed to set at 
4°C for at least 30 mins before use.  Fresh samples were prepared for each study. 
Detailed description of the preparation method can be found in section 2. 
 
6.3.1. Choice of Fabric 
Non-woven polypropylene fabric was used, to give structural integrity to the gel 
(figure 6.11).  Prior to coating the non-woven in solution of gel, the fabric was 
treated with isopropanol or ethanol to remove any residual oil from the fabrication 
process.  
 
Figure 6.11: Light microscope image of untreated polypropylene fabric. Image 
acknowledgements: Neil Poulter, University of Bath Ph.D. Thesis, 2010.  
Backing 




6.3.2. Hypromellose coated fabric 
Hypromellose is a viscos gel, which does not set to form a block (see Chapter 4 for 
details); as a result this gel could not be used for the gel-block system. However, it 
was considered for use in the gel coated fabric system.  
The stability and sensitivity of the system was tested by incubation with bacterial 








Figure 6.12: Showing average well scans of before addition of supernatant and 
after addition of supernatant and overnight incubation at 37°C on hypromellose 
coated systems. 
 
15% TCDA-DS vesicles dispersed in hypromellose system showed stable vesicles in 
HEPES and E. coli DH5α and response to S. aureus MSSA476 and P. aeruginosa 
PAO1. These results were detected by fluorescence intensity measurements as well 
as visual colour difference (figure 6.12), where the wells with lysed vesicles are 
shown to fluoresce and this fluorescence is not visible where the majority of 
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6.3.3. Agarose/Hypromellose gel coated fabric 
The hypromellose gel coated system showed a responsive and stable system, 
however, due to the viscosity of the gel, the gel did not remain on the fabric during 
the overnight study. As a result, in an attempt to aid the binding of the gel to the 
fabric, a gel mixture of agarose and hypromellose was used. The results showed a 
similar pattern to the pure hypromellose system. The agarose/hypromellose 
system was both stable and sensitive (figure 6.13). Despite obtaining desired 










Figure 6.13: Showing average well scans of before addition of supernatant and 
after addition of supernatant and overnight incubation at 37°C on 
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6.3.4. Agarose coated fabric 
The agarose/hypromellose mixture system was difficult to reproduce, therefore a 
pure agarose system was produced and the sensitivity and response was studied. 
The study using bacterial supernatant showed similar responses to the 
hypromellose and the agarose/hypromellose mixture systems, showing stability in 
E. coli DH5α , LB and TSB (negative controls), sensitivity to S. aureus MSSA476, P. 
aeruginosa PAO1 as well as the control, Triton X100.  
Following on from a supernatant study, the agarose coated system was studied for 








Figure 6.14: Showing average well scans of before addition of overnight bacterial 
culture and after overnight incubation at 37°C on agarose gel coated systems. 























































The results to the overnight study showed the desired response and stability. The 
subsequent studies involved different strains of bacteria used within the majority 







Figure 6.15: Average well scans before addition of overnight bacterial culture and 
after 18hr of overnight incubation with shaking at 37°C. Vesicles show both 
fluorescence increase and visible colour change following incubation with AGR+ 
stain of S. aureus. 
 
6.3.5. Summary of gel-coated fabric system 
 
Various hydrogels were used to create the gel-coated fabric system. Stability and 
response of the systems were studied. Results show that all systems showed 
response and stability when incubated with bacterial supernatant overnight. The 
hypromellose/agarose system showed promising results, however reproducibility 
of a uniform distribution of the initial gel mixture was low, therefore this system 
was not selected for further development. The hypromellose system also indicated 
desirable stability and sensitivity; however, the viscosity of the gel prevented the 
gel from being bound to the fabric. This required further improvement for physical 
attachment; as a result, this system was not selected for further studies. The 
agarose system was selected for further development as this system demonstrated 
the desirable stability, sensitivity, physical properties and reproducibility results 
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6.4. First Generation Prototype (FGP) wound dressing 
 
The agarose gel coated non-woven polypropylene with 15% TCDA–DS vesicles 
immobilised system showed most promising results when the data from Chapter 4 
and the data presented in this chapter were combined and analysed. As a result, 
this system was proposed as ‘the first generation wound dressing’.  The response 
of this dressing on addition of bacterial supernatants is shown in figure 6.16. 
 
Figure 6.16: Image of prototype dressing with addition of AGR +/- S. aureus 
supernatant on porcine skin 
 
6.4.1. Improving visual response  
In order to improve the visual response of the agarose dressing, a higher 
concentration of vesicle was used to make the initial gel/vesicle mixture. The 
normal concentration of vesicle solution is approximately 1x1012 particles mL-1; 
the higher concentration of the vesicle is approximately 1x1036 particles/mL. This 
resulted in the use of a triple concentrated solution, thus translating into three 




Figure 6.17: A: agarose coated dressing with lower concentration of vesicles, 
approximately 1x1012. B: agarose coated dressing with higher concentration of 
vesicles, approximately 1x1036 (first generation prototype dressing). HEPES  buffer 
was added to the dressings on the left and Triton X-100 to the dressings on the 
right.  
 
In order to validate the stability and response of the dressings containing the 
higher concentration of vesicles, an overnight assay was conducted using bacterial 
supernatant (figure 6.18). Results display a similar pattern of stability and 
response compared to previous studies involving lower concentration of vesicles. 








Figure 6.18: Average of well scan following overnight incubation with bacterial 
culture. Results show responsive and stable vesicles even when a higher 
concentration of vesicles was incorporated. 
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PAO1 
  




































































6.4.2. Studying the stability of FGP for storage  
 The stability for storage purposes was tested over a period of 21 days at 4°C. On 
the 21st day of the study, Triton X100 was added to ensure sensitivity of vesicles 
following storage. This is shown in figure 6.19, with an SR-parameter value of 13 








Figure 6.19: Average of well scans on Day 1, Day 21 and following addition of 
Triton X100 on Day 21. SR-parameter of 13.2 ±0.222 
  













































6.4.3. FGP on ex vivo skin model  
The response and stability of the prototype dressing on skin was tested on porcine 
as well as human skin obtained from the Bond McIndoe Reseach Foundation. 
6.4.3.1. Response of FGP on Porcine skin 
Response of FGP dressings on infected porcine tissue was assessed. Two methods 
were used to conduct this analysis. First, an overnight bacterial culture was 
directly injected into the tissue sample, without cutting the top layer of the skin; 
the dressings were placed on top of the skin and incubated overnight. The second 
method used an opened layer of the tissue sample, where the top epidermal layer 
was removed, exposing the dermal layer. Overnight cultures were injected into the 
opened dermal layer; dressings were placed on the surface, and incubated 
overnight. Both methods showed lysis of vesicles on incubation of S. aureus 
MSSA476 and P. aeruginosa PAO1 and stability to controls.  Figure 6.19, shows 
images taken before incubation and after 20 h incubation, displaying fluorescent 
dressings on tissue samples infected with pathogenic bacteria, and absence of 
fluorescence on the control. This demonstrates that lysis of vesicles was caused by 
the pathogenic bacteria and that vesicles in the dressing are stable on porcine 
tissue over a period of 20 h at 37°C.  
 
Figure 6.20: image of before incubation and after incubation of FGP dressing on 
tissue injected with overnight bacterial culture. Acknowledgment: W.D. Jamieson 




6.4.3.2. Response of FGP on Human skin 
 
Fresh human skin, obtained following elective procedures in surgical wards, was 
used for this study. The skin was washed in 70% ethanol and cut to obtain desired 
size. The overnight culture was washed in PSB buffer and 500μl of washed culture 
was injected into the tissue to obtain approximately 5x105 CFUmL-1. The FGP 
dressings were placed on top of the injected tissue and incubated over 20 h at 37°C.  
 
Figure 6.21: image of before incubation and after incubation of FGP dressing on 
tissue injected with overnight bacterial culture. 
The verification of response of the FGP dressing was unsuccessful, as vesicles had 
lysed on all tissue samples, including non-toxin producing DH5α lysed over the 
period of 20 h.  The instability of vesicles could be due to a number of different 
reasons; vesicle instability to the proteins present in the tissue sample, 
contamination of sample with antimicrobials and antiseptic residues left on the 
skin from the original procedure conducted.  
The studies involving animal skin were disregarded for further analysis due to lack 







6.4.3.3. Estimating the CFU mL-1 required for lysis of vesicles 
In an attempt to approximate the number of colony forming units required to 
indicate a change in fluorescence of the prototype dressing, animal skin and flesh 
samples were used. The prototype dressings were placed on top of pre-infected 
porcine skin and beef steak models with the three standard bacterial models, S. 
aureus MSSA476, P. aeruginosa PAO1 and E. coli DH5α. Fluorescence 
measurements of the dressings were taken at 2, 4, 6 and following 20h incubation 
at 37°C. This work was carried out by an undergraduate student as part of a final 
year project at the Department of Chemistry, University of Bath.  
Table 6.1 displays the SR-parameter values obtained as well as the corresponding 
values of the CFU mL-1 of bacteria required. The results of the assay carried out on 
bovine tissue show that in order to obtain an SR-parameter of 10.5 and 12.0 by P. 
aeruginosa PAO1 and S. aureus MSSA476 respectably, bacterial concentration in 
the magnitude of 107 CFU mL-1 was required. The same assay carried out on 
porcine tissue showed an SR-value of 50.9 at 5.6x105 CFU mL-1. The results suggest 
that the dressings can be used to indicate the present of bacterial colonies on 
animal tissue.  
Table 6.1: SR-values and colony forming units  




Porcine Tissue E. coli DH5α 22.9 1.6x104 
Porcine Tissue S. aureus MSSA 476 38.3 8.0x106 
Porcine Tissue P. aeruginosa PAO1 50.9 5.6x105 
Porcine Tissue 
Bovine Tissue 
LB 26.0 No growth 
E. coli DH5α 1.55 1.7x104 
Bovine Tissue S. aureus MSSA 476 12.0 4.7x107 
Bovine Tissue P. aeruginosa PAO1 10.5 1.7x107 







6.5. Second generation prototype (SGP) wound dressing 
 
As previously mentioned in Chapter one and at the beginning of this Chapter, the 
wound healing property of a dressing is a desirable characteristic, especially for a 
burn wound. As a result, the FGP dressing was further embellished by addition of a 
cell growth-enhancing layer to give rise to a second generation prototype wound 
dressing (SGP).  
 
6.5.1. Collagen based biological dressing 
The advantages of using collagen based biological dressings in the management of 
burns have been shown by previous studies5,6. Collagen is an essential component 
in cellular adhesion and migration within the natural wound healing process.  
Collagen is naturally produced by the human body as an extra cellular matrix to aid 
migration and binding of keratinocytes. Cells have integrin for cell to cell binding 
as well as cell to extra cellular matrix binding. Collagen contains numerous integrin 
binding sites for this to occur. As a result the collagen layer on the dressing should 
theoretically enhance cell migration towards the dressing, and upon migration, 
encourage cell binding, which in turn should promote further cell migration and 













6.5.2. Proposed mechanism of wound healing enhancement by SGP 
 
 
Figure 6.23: Representation of wound healing being promoted by second 
generation dressing (collagen dressing) 
 
As previously discussed, wound healing occurs from the outer side of the wound 
site towards the middle. Thus, in larger injuries, the middle of the wound is 
exposed for a longer period of time hence the chances of infection is increased. The 
proposed wound dressing acts to enhance wound healing throughout the entire 
wound bed by means of a collagen coating (figure 6.23). 
 
6.5.3. Experimental results of cell growth on SGP 
The cell attachment property and growth property of the SGP dressing was studied 
using HaCaT and Ea.hy926 cells. The initial attachment was verified by seeding a 
large cell density onto the wound dressing, followed by 1h incubation and removal 
of the solution and washing with PBS. In order to assess the growth, media was 
replenished and the cells were incubated at 37°C with 5% CO2 over 48s. Following 
48h incubation, resazurin assay was used to measure cell respiration. As controls, 
the same procedure was carried using the FGP dressing and a blank surface (non-
adherent to cells) to ensure that growth of cells was due to the collagen and to 











Figure 6.24: Eukaryotic cell growth on black surface (non-adherent to cells), 
agarose coated fabric and collagen coated agarose coated fabric normalised against 
maximum cell growth of tissue culture plate. Both HaCaT and Eayh926 cell lines 
show improved attachment on collagen coated dressing compared to simple 
agarose coated fabric. Statistical analysis were carried out by a Student’s t-test, * P- 
value > 0.05, **P- value < 0.05 
 
Figure 6.24 displays data indicating that with the additional collagen layer, there 
was a 65% cell growth observed for HaCaT cells and 42% growth for EA.hy926. 
Whereas on the FGP dressings, growth of only 20% was observed for HaCaTs, and 
growth of 10% was identified for EA.hy926 cells. Furthermore, the growth of both 
types of cells on the blank plates was negligible.   
  




































6.6. Conclusion  
In this Chapter, two major types of dressing prototypes were looked at, the gel-
block system and the gel-coated fabric system. The coated fabric system was 
favoured over the gel-block system due to the slow diffusion of lysing agents on 
thick gels and brittle mechanical properties of the thin gels. Out of the several gel-
coated systems, the agarose gel was selected due to results showing stability and 
sensitivity of vesicles as well as reproducibility of these results. The visual 
response of the agarose-gel coated fabric was improved by the use of higher 
concentration of vesicles and produced the first generation prototype dressing 
(FGP). The in vitro response of FGP was assessed using infected animal skin models. 
Furthermore, FGP dressing was further embellished by an additional collagen 
coating was added, which was shown, by in vitro studies, to improve the cell 
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7.1. Conclusions and Future work 
The initial aim of this project was to develop a pathogenic bacterial detection 
system to incorporate into a wound dressing with wound healing properties. This 
was to be used for management of paediatric burns, where bacterial infection can 
be lethal. 
During the course of this research, a stable in various different pH and 
temperature ranges as well as in a eukaryotic cellular environment and sensitive 
to pathogenic bacteria system was developed. The system consisted of 15% TCDA, 
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20% cholesterol, 2% DSPE and 63% DSPC. This phospholipid based sensor was 
successfully immobilised and developed in an initial prototype wound dressing 
(FGP) consisting of a gel coated non-woven polypropylene fabric. This was then 
further enhanced with an additional collagen coating to yield the final SGP dressing 
with the potential ability to enhance cell growth, thus promote wound healing.  
Although the SGP dressing have shown desirable stability and response, the 
thickness of the gel and the lack of transparency of the prototype remain as a 
weakness. As diffusion was the main difficulty involving the gel-block system, the 
fabric was used as a scaffold for the vesicles embedded hydrogel to increase 
surface area exposed to pathogenic bacterial supernatant/ toxins. However, the 
presence of the fabric can block the fluorescence increase, thus the dressing can be 
improved through the use of a fabric with larger holes, such as woven cotton fabric. 
Moreover, a gel-block type system can be developed using a high crosslinked 
hydrogel system with larger pores, allowing for faster diffusion of vesicle lysing 
agents.  
The response of the vesicle to multiple strains of bacteria was tested by other 
members of the group; however, the response of entire prototype was only carried 
out on a limited number of pathogenic bacteria. Thus, a detailed analysis of 
response of the prototype to a wide range of pathogens may be beneficial. 
Furthermore, the cell growth assays on the SGP dressings were only carried out 
over a period of 48h, thus only showing the proliferation process of cell. Future 





7.2. Demand for new methods to combat/prevent infections  
 
In 2004, there were 11 million burn incidents reported globally; of this population, 
153 per 100,000 occurred on children under the age of 15 with 20% TBSA1. 
Globally, approximately 19,000 children are admitted to hospitals every year for 
treatment of burn injuries2, and as previously stated, the majority of these injuries 
are hot liquid scalds. As well as the trauma caused to the patient and their family, 
the cost of the treatment is tremendous if hospitalisation is required.  
7.2.1. Infections and Antimicrobial resistance  
As previously stated in Chapter one, one of the main concerns over a burn injury is 
the risk of development of an infection, which can prove fatal unless the infection 
is rapidly diagnosed and timely and appropriate treatment administered.  
Antibiotics can be prescribed on suspicion of an infected wound; however 
indiscriminate use of antibiotics has been known to be one of the leading causes of 
development of antibiotic resistance3. Furthermore, the typical treatment of burn 
infection involves administration of broad spectrum antibiotics, which can add to 
the build-up of antibiotic resistance.   
 
7.2.2. Economics of development of new antibiotics  
The main theme of the World Health Day in 2011 was ‘antimicrobial resistance: no 
action today and no cure tomorrow’4. Despite  the high demand for new antibiotics, 
large Pharmaceutical industries have reduced investment into development of new 
classes of antibiotics due to the supposed lack of return on investment5.  These low 
returns are likely caused by the legislated controlled use, in order to minimise 
further development of antibiotic resistance, but is also related to rapid 
development of resistance, causing a discontinued use of the newly developed 




7.3. Health-economics of development of a new dressing  
 
The dressing being developed by this research will not only aid prevention of 
further development of antibiotic resistance, but also help towards minimising the 
cost involved in the treatment of burns.  
 
7.3.1. Cost involved in treatment of burns  
The South West Paediatric Burn service in Bristol conducted a survey on the cost 
of treatment of 144 patients admitted with scalds. The cost of treatment of minor 
burns, affecting less than 10% of total body surface area (TBSA), showed an 
average cost of £ 1850. The cost involving major scalds, affecting more than 10% 
TBSA, showed a cost ranging from £55,354.79 to £74,494.24, giving a mean of 
£63,157.22 per patient. The cost involved arises from long hospital stays, intensive 
care stays, visits to the operating theatre with general anaesthesia for initial 
assessment and scrubbing of the wound site, application of biological wound 
dressings, possible skin grafting, and the use of antibiotics7. Besides these, this data 
does not include the cost of posttraumatic wound and scar management and the 
multiple visits for physiotherapy required following a major burn8.  








Table 7.1 shows the average cost involved in treatment of paediatric scald as well 
as the breakdown of the cost. The study was limited minor to less than 10% TBSA 
Treatment Average cost (£) 
Hospital bed 1195 
Theatre visit 539 
Medication used 2 
Dressings used 114 
Total  1850 
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burns and neglected to include the cost of scar management post burn. The 
average total cost was found to be £1850, of which the majority of the cost 
involved was due to hospitalisation.9 Demonstrating that minimising     




7.4. The proposed solution: commercialisation of the  
prototype dressing   
 
The aim of this research was to develop a novel wound dressing which can signal 
the presence of pathogenic bacteria by detection of lytic proteins produced by the 
bacteria, as well as to enhance the healing process of the wound by encouraging 
cell growth around the injured area. The dressing was designed with the aim to aid 
wound healing as a result of burns, specifically scalds.  
The dressing components have been tested for their potential cytotoxic effects to 
eukaryotic cells, via in vitro analysis, which showed negligible cytotoxic effects. The 
assessment of stability and sensitivity of the dressing on skin was attempted in an 
in vitro assay using porcine skin as well as human tissue, however results were 
inconclusive. As a result, at present, the behaviour of the dressings on infected 
tissue is yet to be explored.  
According to the regulations provided by the Food and Drugs Administration 
(FDA), a medical device is an instrument which is ‘intended for use in the diagnosis 
of disease or other conditions’ as well as affecting the function or the structure of 
the body. Therefore, the dressing being developed in this study can be classified as 
a medical device, as it is intended to use for diagnosis of burn infection, by use of 
bacterial toxin sensitive nanosensors, and intended to affect the structure of the 
injured body through enhancing the healing process by stimulating cell migration 
on the surface of the wound.10  
As the prototype developed in this study can be classified as a medical device, 
Good Manufacturing Practices have to be followed.  
 
7.4.1. Clinical trials 
Clinical trials have to be conducted in accordance with the Helsinki agreements11 
and the FDA’s requirements for protection of human subjects; clinical trials 
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conducted on children have additional safety requirements. Further detail can be 
found on the FDA information sheets provided by the agency10,12.  
In general pre-clinical studies are conducted on small and large animals prior to 
conducting trials on human subjects.    
 
7.4.1.1. Pre-clinical phase studies  
In order to further assess the wound healing properties of the prototype dressing, 
the dressings must be tested on real wounds. For this, research using animals has 
to be conducted prior to conducting clinical assessments on humans. The stability 
and sensitivity of dressings on porcine, bovine and human skin must be assessed. 
7.4.1.2. Pre-clinical Phase studies on small animals  
Prior to conducting clinical tests on humans, pre-clinical studies are required to be 
conducted though a number of different stages. Primarily, pre-clinical in-vivo 
studies on small animals to evaluate biocompatibility, analysis of the migratory 
pathways of inflammatory cells and their interaction with bacteria on infected 
models, and the response of the dressing to bacterial toxins in the presence of 
inflammatory cells. Mouse and rats are often used for conducting these studies, as 
they are relatively inexpensive, have a short life-cycle giving rise to collections of 
reproducible data13.   
7.4.1.3. Pre-clinical Phase studies on large animals  
Following studies on small animals, studies on larger animals can provide evidence 
on safety and effectiveness of the dressing. Pigs have often been used as models to 
study wound healing effects of dressings. The physiological, anatomical and 
epidemiological factors of porcine skin have been known to resemble human skin, 
allowing closely relating outcomes when used as models14,15,16. Figure 7.1 shows 
the comparison of histological features of human and porcine tissue indicating 
similarities in the thickness of epidermal and dermal layers.  
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Figure 7.1: Histological features of human and porcine skin. Sections were taken 
through comparable portions of the dermis of both tissue samples.  Images 
modified from article by Sullivan et al. 14 
Furthermore, Sullivan et al. presented porcine burn models for studying the effect 
of different methods of treatment on wound healing of burns17.  
The pre-clinical assessments on animals will provide data on biocompatibility of 
the dressings, data on immune response and the effects on stability and activity of 
the dressings, effectiveness of the dressing in detecting bacterial toxins in the 
presence of inflammatory cells, as well as the effectiveness of the collagen layer in 
aiding the wound healing process.  
7.4.1.4. Clinical trials on humans  
Upon successful completion of pre-clinical phase studies on animal models, clinical 
studies on humans can be started. In general, there are four different phases to the 
clinical trials, phases 1 to 4. Phase 1 investigates the safety of a particular device or 
drug being developed and phases 2 through to 4 generally examine the efficacy of 
the product, including the use of placebos for accurate evaluation of effectiveness 













In summary, the dressing being developed through this research can be classified 
as a medical device, used as a diagnostic tool for bacterial infection as well as a 
material to aid the re-epithelialisation process of wounds. The dressing was 
initially designed for paediatric scalds; however, it has the potential to be used as a 
dressing for any type of skin injury with a high risk of development of a bacterial 
infection.   
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